Thermo Fisher Scientific (TMO) 10-K 20 Feb 25 2024 FY Annual report Financial data

Cover

Cover - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Feb. 01, 2025	Jun. 28, 2024
Entity Listings [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-8002
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2209186
Entity Address, Address Line One	168 Third Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	622-1000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 211,032,682
Entity Common Stock, Shares Outstanding		377,261,182
Documents Incorporated by Reference [Text Block]	Sections of Thermo Fisher’s definitive Proxy Statement for the 2025 Annual Meeting of Shareholders (the “Proxy Statement”) are incorporated by reference into Part III of this report.
Entity Central Index Key	0000097745
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Common Stock, $1.00 par value
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Entity Stock Trading Symbol	TMO
Security Exchange Name	NYSE
0.125% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	0.125% Notes due 2025
Entity Stock Trading Symbol	TMO 25B
Security Exchange Name	NYSE
2.000% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	2.000% Notes due 2025
Entity Stock Trading Symbol	TMO 25
Security Exchange Name	NYSE
3.200% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	3.200% Notes due 2026
Entity Stock Trading Symbol	TMO 26B
Security Exchange Name	NYSE
1.400% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	1.400% Notes due 2026
Entity Stock Trading Symbol	TMO 26A
Security Exchange Name	NYSE
1.450% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.450% Notes due 2027
Entity Stock Trading Symbol	TMO 27
Security Exchange Name	NYSE
1.750% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2027
Entity Stock Trading Symbol	TMO 27B
Security Exchange Name	NYSE
0.500% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	0.500% Notes due 2028
Entity Stock Trading Symbol	TMO 28A
Security Exchange Name	NYSE
1.375% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	1.375% Notes due 2028
Entity Stock Trading Symbol	TMO 28
Security Exchange Name	NYSE
1.950% Notes due 2029
Entity Listings [Line Items]
Title of 12(b) Security	1.950% Notes due 2029
Entity Stock Trading Symbol	TMO 29
Security Exchange Name	NYSE
0.875% Notes due 2031
Entity Listings [Line Items]
Title of 12(b) Security	0.875% Notes due 2031
Entity Stock Trading Symbol	TMO 31
Security Exchange Name	NYSE
2.375% Notes due 2032
Entity Listings [Line Items]
Title of 12(b) Security	2.375% Notes due 2032
Entity Stock Trading Symbol	TMO 32
Security Exchange Name	NYSE
3.650% Notes due 2034
Entity Listings [Line Items]
Title of 12(b) Security	3.650% Notes due 2034
Entity Stock Trading Symbol	TMO 34
Security Exchange Name	NYSE
2.875% Notes due 2037
Entity Listings [Line Items]
Title of 12(b) Security	2.875% Notes due 2037
Entity Stock Trading Symbol	TMO 37
Security Exchange Name	NYSE
1.500% Notes due 2039
Entity Listings [Line Items]
Title of 12(b) Security	1.500% Notes due 2039
Entity Stock Trading Symbol	TMO 39
Security Exchange Name	NYSE
1.875% Notes due 2049
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2049
Entity Stock Trading Symbol	TMO 49
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Audit Information [Abstract]
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Boston, Massachusetts

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,009	$ 8,077
Short-term investments	1,561	3
Accounts receivable, less allowances of $173 and $193	8,191	8,221
Inventories	4,978	5,088
Contract assets, net	1,435	1,443
Other current assets	1,964	1,757
Total current assets	22,137	24,589
Property, plant and equipment, net	9,306	9,448
Acquisition-related intangible assets, net	15,533	16,670
Other assets	4,492	3,999
Goodwill	45,853	44,020
Total assets	97,321	98,726
Current liabilities:
Short-term obligations and current maturities of long-term obligations	2,214	3,609
Accounts payable	3,079	2,872
Accrued payroll and employee benefits	1,988	1,596
Contract liabilities	2,852	2,689
Other accrued expenses	3,199	3,246
Total current liabilities	13,332	14,012
Deferred income taxes	1,268	1,922
Other long-term liabilities	3,989	4,642
Long-term obligations	29,061	31,308
Commitments and contingencies (Note 5)
Redeemable noncontrolling interest	120	118
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 443,841,240 and 442,188,634 shares issued	444	442
Capital in excess of par value	17,962	17,286
Retained earnings	53,102	47,364
Treasury stock at cost, 63,066,906 and 55,541,290 shares	(19,226)	(15,133)
Accumulated other comprehensive income/(loss)	(2,697)	(3,224)
Total Thermo Fisher Scientific Inc. shareholders’ equity	49,584	46,735
Noncontrolling interests	(33)	(11)
Total equity	49,551	46,724
Total liabilities, redeemable noncontrolling interest and equity	$ 97,321	$ 98,726

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 173	$ 193
Preferred Stock, $0 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $0 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $0 Par Value - Shares Issued (in shares)	0	0
Common Stock, $0 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $0 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $0 Par Value - Shares Issued (in shares)	443,841,240	442,188,634
Treasury Stock at Cost (in shares)	63,066,906	55,541,290

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total revenues	$ 42,879	$ 42,857	$ 44,915
Costs and operating expenses:
Selling, general and administrative expenses	8,595	8,445	8,993
Research and development expenses	1,390	1,337	1,471
Restructuring and other costs	379	459	114
Total costs and operating expenses	35,542	35,998	36,522
Operating income	7,337	6,859	8,393
Interest income	1,078	879	272
Interest expense	(1,390)	(1,375)	(726)
Other income/(expense)	12	(65)	(104)
Income before income taxes	7,037	6,298	7,835
Benefit from/(provision for) income taxes	(657)	(284)	(703)
Equity in earnings/(losses) of unconsolidated entities	(42)	(59)	(172)
Net income	6,338	5,955	6,960
Less: net income (losses) attributable to noncontrolling interests and redeemable noncontrolling interest	3	(40)	10
Net income attributable to Thermo Fisher Scientific Inc.	$ 6,335	$ 5,995	$ 6,950
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic (in dollars per share)	$ 16.58	$ 15.52	$ 17.75
Diluted (in dollars per share)	$ 16.53	$ 15.45	$ 17.63
Weighted average shares
Basic (in shares)	382	386	392
Diluted (in shares)	383	388	394
Product revenues
Revenues
Total revenues	$ 25,034	$ 25,243	$ 28,548
Costs and operating expenses:
Cost of revenues	12,523	13,168	14,247
Service revenues
Revenues
Total revenues	17,845	17,614	16,367
Costs and operating expenses:
Cost of revenues	$ 12,654	$ 12,589	$ 11,697

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Comprehensive income
Net income	$ 6,338	$ 5,955	$ 6,960
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $317, $(134) and $173)	525	(69)	(822)
Unrealized gains and losses on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax benefit of $1, $2 and $1)	3	5	2
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $2, $(22) and $9)	(12)	(69)	38
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $1, $1 and $3)	4	0	5
Total other comprehensive income/(loss)	520	(133)	(777)
Comprehensive income	6,858	5,822	6,183
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest	(4)	(48)	3
Comprehensive income attributable to Thermo Fisher Scientific Inc.	$ 6,862	$ 5,870	$ 6,180

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ 317	$ (134)	$ 173
Tax provision (benefit) on reclassification adjustment for losses included in net income	(1)	(2)	(1)
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period	2	(22)	9
Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost	$ 1	$ 1	$ 3

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating activities
Net income	$ 6,338	$ 5,955	$ 6,960
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	1,156	1,068	986
Amortization of acquisition-related intangible assets	1,952	2,338	2,395
Change in deferred income taxes	(1,209)	(1,300)	(995)
Stock-based compensation	301	278	307
Other net non-cash expenses	508	604	550
Changes in assets and liabilities, excluding the effects of acquisitions:
Accounts receivable	(171)	(43)	(430)
Inventories	(27)	598	(825)
Contract assets/liabilities	(162)	252	(354)
Accounts payable	212	(500)	648
Contributions to retirement plans	(45)	(42)	(41)
Other	(186)	(802)	(47)
Net cash provided by operating activities	8,667	8,406	9,154
Investing activities
Purchases of property, plant and equipment	(1,400)	(1,479)	(2,243)
Proceeds from sale of property, plant and equipment	57	87	24
Proceeds from cross-currency interest rate swap interest settlements	252	70	15
Acquisitions, net of cash acquired	(3,132)	(3,660)	(39)
Purchases of investments	(3,396)	(208)	(52)
Proceeds from sales and maturities of investments	1,770	15	116
Other investing activities, net	8	33	20
Net cash used in investing activities	(5,841)	(5,142)	(2,159)
Financing activities
Net proceeds from issuance of debt	1,204	5,942	3,193
Repayment of debt	(3,607)	(5,782)	(375)
Proceeds from issuance of commercial paper	0	1,620	1,526
Repayments of commercial paper	0	(1,935)	(3,690)
Purchases of company common stock	(4,000)	(3,000)	(3,000)
Dividends paid	(583)	(523)	(455)
Other financing activities, net	195	56	(9)
Net cash used in financing activities	(6,792)	(3,622)	(2,810)
Exchange rate effect on cash	(91)	(82)	(139)
(Decrease) increase in cash, cash equivalents and restricted cash	(4,057)	(440)	4,046
Cash, cash equivalents and restricted cash at beginning of year	8,097	8,537	4,491
Cash, cash equivalents and restricted cash at end of year	$ 4,040	$ 8,097	$ 8,537

CONSOLIDATED STATEMENTS OF REDE

CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY - USD ($) $ in Millions	Total	Total Thermo Fisher Scientific Inc. Shareholders’ Equity	Common Stock	Capital in Excess of Par Value	Retained Earnings	Treasury Stock	Accumulated Other Comprehensive Items	Noncontrolling Interests
Beginning Balance at Dec. 31, 2021	$ 122
Redeemable Noncontrolling Interest [Roll Forward]
Net income/(loss)	15
Other comprehensive income/(loss)	(6)
Contributions from (distributions to) noncontrolling interests	(15)
Ending Balance at Dec. 31, 2022	116
Balance (in shares) at Dec. 31, 2021			439,000,000
Beginning Balance at Dec. 31, 2021	40,855	$ 40,793	$ 439	$ 16,174	$ 35,431	$ (8,922)	$ (2,329)	$ 62
Treasury stock beginning balance (in shares) at Dec. 31, 2021						45,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under stock plans (in shares)			2,000,000
Issuance of shares under stock plans	169	169	$ 2	262		$ (95)
Stock-based compensation	307	307		307
Purchases of company common stock (in shares)						5,000,000
Purchases of company common stock	(3,000)	(3,000)				$ (3,000)
Dividends declared	(471)	(471)			(471)
Net income/(loss)	6,945	6,950			6,950			(5)
Other comprehensive income/(loss)	(771)	(770)					(770)	(1)
Contributions from (distributions to) noncontrolling interests	(2)							(2)
Balance (in shares) at Dec. 31, 2022			441,000,000
Treasury stock ending balance (in shares) at Dec. 31, 2022						50,000,000
Ending Balance at Dec. 31, 2022	44,032	43,978	$ 441	16,743	41,910	$ (12,017)	(3,099)	54
Redeemable Noncontrolling Interest [Roll Forward]
Net income/(loss)	19
Other comprehensive income/(loss)	(3)
Contributions from (distributions to) noncontrolling interests	(14)
Ending Balance at Dec. 31, 2023	118
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under stock plans (in shares)			1,000,000			1,000,000
Issuance of shares under stock plans	178	178	$ 1	265		$ (88)
Stock-based compensation	278	278		278
Purchases of company common stock (in shares)						5,000,000
Purchases of company common stock	(3,000)	(3,000)				$ (3,000)
Dividends declared	(541)	(541)			(541)
Net income/(loss)	5,936	5,995			5,995			(59)
Other comprehensive income/(loss)	(130)	(125)					(125)	(5)
Contributions from (distributions to) noncontrolling interests	(1)							(1)
Excise tax from stock repurchases	$ (28)	(28)				$ (28)
Balance (in shares) at Dec. 31, 2023			442,000,000
Treasury stock ending balance (in shares) at Dec. 31, 2023	55,541,290					56,000,000
Ending Balance at Dec. 31, 2023	$ 46,724	46,735	$ 442	17,286	47,364	$ (15,133)	(3,224)	(11)
Redeemable Noncontrolling Interest [Roll Forward]
Net income/(loss)	23
Other comprehensive income/(loss)	(6)
Contributions from (distributions to) noncontrolling interests	(14)
Ending Balance at Dec. 31, 2024	120
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under stock plans (in shares)			2,000,000			0
Issuance of shares under stock plans	310	310	$ 2	376		$ (67)
Stock-based compensation	301	301		301
Purchases of company common stock (in shares)						7,000,000
Purchases of company common stock	(4,000)	(4,000)				$ (4,000)
Dividends declared	(596)	(596)			(596)
Net income/(loss)	6,315	6,335			6,335			(20)
Other comprehensive income/(loss)	527	527					527	0
Contributions from (distributions to) noncontrolling interests	(1)							(1)
Excise tax from stock repurchases	$ (26)	(26)				$ (26)
Balance (in shares) at Dec. 31, 2024			444,000,000
Treasury stock ending balance (in shares) at Dec. 31, 2024	63,066,906					63,000,000
Ending Balance at Dec. 31, 2024	$ 49,551	$ 49,584	$ 444	$ 17,962	$ 53,102	$ (19,226)	$ (2,697)	$ (33)

CONSOLIDATED STATEMENTS OF RE_2

CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Cash dividends declared per common share (in dollars per share)	$ 1.56	$ 1.40	$ 1.20

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Principles of Consolidation The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. Redeemable Noncontrolling Interest The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events. Presentation Certain reclassifications of prior year amounts have been made to conform to the current year presentation. Amounts and percentages reported within these consolidated financial statements are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates. Cash and Cash Equivalents Cash equivalents consists principally of money market funds and other marketable securities purchased with a remaining maturity of three months or less. These investments are carried at cost, which approximates market value (see Note 4). Inventories Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. The company periodically reviews quantities of inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer costs, are included in cost of revenues in the accompanying statement of income. Contract-related Balances Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers. Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract. Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively (see Note 2). Property, Plant and Equipment Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements, the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Acquisition-related Intangible Assets Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value. In addition, the company has tradenames that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if applicable. Investments Investments include marketable securities, such as marketable equity securities, available for sale debt securities, and bank time deposits with maturities greater than three months, equity method investments, and non-marketable equity investments. The company classifies investments as current or noncurrent based on the nature of the securities and their availability for use in current operations. Noncurrent investments are included in other assets. Marketable securities are stated at fair value with all realized and unrealized gains and losses on investments in marketable equity securities and realized gains and losses on available-for-sale debt securities recognized in other income/(expense). The company accounts for investments in businesses using the equity method when it has the ability to exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value option. The company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted for under the equity method (see Note 2). The company’s share of gains and losses in, and impairments of, equity method investments are recorded in equity in earnings (losses) of unconsolidated entities. Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the same issuer. The company performs qualitative assessments to identify impairments of these investments. All gains and losses on non-equity method investments are recognized in other income/(expense). Other Assets Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, insurance recovery receivables related to product liability matters, certain intangible assets and other assets. Goodwill The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the quantitative goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2024, 2023 or 2022. Fair Value Measurements Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves. Level 3: Inputs are unobservable data points that are not corroborated by market data. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair values of contingent consideration are recorded in selling, general and administrative expense. The company determines the fair value of its equity method and non-marketable equity investments that are not eligible for the NAV practical expedient by considering factors such as financial position, operating results and cash flows of the investee; recent transactions in the same or similar securities; significant recent events affecting the investee; the price paid by Thermo Fisher; among others. Loss Contingencies Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. The company determines the probability and range of possible loss for its litigation and other contingencies based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Warranty Obligations The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred. Foreign Currency Translation All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period. Revenue Recognition Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. However, some modifications are distinct from existing services provided under the contract and recognized prospectively. Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues. Research and Development The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred. Restructuring Costs Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models. From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to provide economic benefits to the company. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period. Earnings per Share Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units (see Note 6). Income Taxes The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused. The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money (see Note 7). Derivative Contracts The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings. The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, Canadian dollars, British pounds sterling, Swedish krona, Singapore dollars, Hong Kong dollars and Swiss franc. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management. Cash flow hedges . For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings. Net investment hedges. The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheets under the caption other assets or other long-term liabilities. The fair value of the currency exchange contracts is included in the accompanying balance sheets under the captions other current assets or other accrued expenses. Leases Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense. Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. As a lessee, the company accounts for the lease and non-lease components as a single lease component (see Note 13). Pension and Other Postretirement Benefit Plans The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost/(income). Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost/(income). When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits. The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. The discount rate used to determine projected benefit obligations and net periodic pension benefit cost/(income) reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan. The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. The expected long-term rate of return on plan assets used to determine net periodic pension benefit cost/(income) reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks. Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements. The expected rate of compensation increase used to determine net periodic pension benefit cost/(income) reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases (see Note 14). Stock-based Compensation Expense Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses. The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate is calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures. Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Balance Sheet Information	Supplemental Balance Sheet Information Inventories The components of inventories are as follows: (In millions) December 31, 2024 December 31, 2023 Raw materials $ 1,803 $ 2,057 Work in process 755 705 Finished goods 2,420 2,326 Inventories $ 4,978 $ 5,088 Contract-related Balances Contract asset and liability balances are as follows: (In millions) December 31, 2024 December 31, 2023 Current contract assets, net $ 1,435 $ 1,443 Noncurrent contract assets, net 6 4 Current contract liabilities 2,852 2,689 Noncurrent contract liabilities 1,138 1,499 Substantially all of the current contract liabilities balance at December 31, 2023 and 2022 was recognized in revenues during 2024 and 2023, respectively. Noncurrent contract liabilities decreased during 2024 primarily due to a customer contract modification. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2024 was $24.61 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 53% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three Property, Plant and Equipment Property, plant and equipment consists of the following: (In millions) December 31, 2024 December 31, 2023 Land $ 439 $ 458 Buildings and improvements 3,728 3,593 Machinery, equipment and leasehold improvements 9,858 9,235 Construction in progress 2,034 2,238 Property, plant and equipment, at cost 16,059 15,524 Less: Accumulated depreciation and amortization 6,753 6,076 Property, plant and equipment, net $ 9,306 $ 9,448 Acquisition-related Intangible Assets Acquisition-related intangible assets are as follows: Balance at December 31, 2024 Balance at December 31, 2023 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite lived: Customer relationships $ 22,644 $ (10,047) $ 12,596 $ 22,762 $ (9,410) $ 13,352 Product technology 5,557 (4,423) 1,134 5,894 (4,591) 1,303 Tradenames 1,706 (1,180) 527 1,634 (1,079) 555 Backlog 1,084 (1,043) 41 1,084 (859) 225 30,991 (16,693) 14,298 31,374 (15,939) 15,435 Indefinite lived: Tradenames 1,235 N/A 1,235 1,235 N/A 1,235 Acquisition-related intangible assets $ 32,226 $ (16,693) $ 15,533 $ 32,609 $ (15,939) $ 16,670 The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2024 is as follows: (In millions) 2025 $ 1,665 2026 1,496 2027 1,467 2028 1,436 2029 1,324 2030 and thereafter 6,911 Estimated future amortization expense of definite-lived intangible assets $ 14,298 At December 31, 2024 and 2023, the company had $34 million and $37 million, respectively, of intangible assets not derived from acquisitions, net of accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. Other Assets At December 31, 2024 and 2023, the company had equity method investments with carrying amounts of $357 million and $489 million, respectively. At December 31, 2024 and 2023, the fair value of investments for which the company has elected the fair value option was $0 million and $5 million, respectively. At December 31, 2024 and 2023, the company’s equity investments that do not have readily determinable fair values and are not eligible for the NAV practical expedient investments had carrying amounts of $41 million and $12 million, respectively. Investments measured at NAV were $40 million and $28 million at December 31, 2024 and 2023, respectively. Goodwill The changes in the carrying amount of goodwill by segment are as follows: (In millions) Life Sciences Analytical Specialty Laboratory Total Balance at December 31, 2022 $ 10,146 $ 4,965 $ 3,091 $ 22,994 $ 41,196 Acquisitions — 31 1,741 627 2,399 Currency translation 5 55 91 274 425 Balance at December 31, 2023 10,151 5,051 4,923 23,895 44,020 Acquisitions 2,302 — — — 2,302 Currency translation (117) (92) (139) (122) (470) Balance at December 31, 2024 $ 12,336 $ 4,959 $ 4,784 $ 23,773 $ 45,853

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements	Debt and Other Financing Arrangements The company’s debt and other financing arrangements are as follows: Effective interest rate at December 31, December 31, December 31, (Dollars in millions) 2024 2024 2023 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) $ — $ 1,104 1.215% 3-Year Senior Notes, Due 10/18/2024 — 2,500 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.40 % 828 883 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.07 % 663 706 0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated) 1.05 % 142 158 0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) 0.14 % 569 607 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) 3.38 % 518 552 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.52 % 725 773 4.953% 3-Year Senior Notes, Due 8/10/2026 5.18 % 600 600 5.000% 3-Year Senior Notes, Due 12/5/2026 5.26 % 1,000 1,000 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.64 % 518 552 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.96 % 621 662 1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated) 1.18 % 184 205 4.80% 5-Year Senior Notes, Due 11/21/2027 5.00 % 600 600 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.76 % 828 883 1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated) 1.79 % 364 — 0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated) 0.90 % 184 206 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 621 662 1.750% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 700 5.000% 5-Year Senior Notes Due 1/31/2029 5.24 % 1,000 1,000 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.07 % 725 773 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated) 1.44 % 30 33 4.977% 7-Year Senior Notes, Due 8/10/2030 5.12 % 750 750 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 0.88 % 1,812 1,932 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 932 993 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 1,200 1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated) 1.92 % 457 — 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.54 % 621 662 Effective interest rate at December 31, December 31, December 31, (Dollars in millions) 2024 2024 2023 1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated) 1.60 % 40 45 4.95% 10-Year Senior Notes, Due 11/21/2032 5.09 % 600 600 5.086% 10-Year Senior Notes, Due 8/10/2033 5.20 % 1,000 1,000 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 1.20 % 1,553 1,656 5.200% 10-Year Senior Notes, Due 1/31/2034 5.34 % 500 500 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) 3.76 % 777 828 1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated) 1.58 % 137 152 2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated) 2.10 % 358 — 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 725 773 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 932 993 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 1,200 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 1.76 % 1,294 1,380 2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated) 2.13 % 93 104 5.404% 20-Year Senior Notes, Due 8/10/2043 5.50 % 600 600 2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated) 2.06 % 184 206 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,035 1,104 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 2.06 % 777 828 2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated) 2.43 % 212 236 Other 73 77 Total borrowings at par value 31,332 35,028 Unamortized discount (95) (113) Unamortized debt issuance costs (164) (188) Total borrowings at carrying value 31,072 34,727 Finance lease liabilities 202 190 Less: Short-term obligations and current maturities 2,214 3,609 Long-term obligations $ 29,061 $ 31,308 The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs. See Note 4 for fair value information pertaining to the company’s long-term borrowings. As of December 31, 2024, the annual repayment requirements for debt obligations are as follows: (In millions) Borrowings Finance Lease Liabilities 2025 $ 2,202 $ 12 2026 2,843 12 2027 1,923 10 2028 2,726 9 2029 2,655 8 2030 and thereafter 18,983 151 $ 31,332 $ 202 In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $65 million as of December 31, 2024. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates. Credit Facilities The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), a Euro Interbank Offered Rate (EURIBOR)-based rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2024, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. Senior Notes Interest is payable annually on the euro and Swiss franc-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S. dollar, euro-denominated fixed rate senior notes and yen-denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of yen-denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants related to its senior notes at December 31, 2024. In 2022 the company completed the full allocation of an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in whole or in part, certain COVID-19 response projects. In 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption, the company incurred $26 million of losses on the early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes outstanding as of December 31, 2024, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due 2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company. January 2025 Debt Issuances In the first quarter of 2025 the company issued the following senior notes: (In millions) Principal Value Issued 0.790% 3-Year Senior Notes, Due January 6, 2028 (Swiss franc-denominated) Fr. 88 1.120% 5-Year Senior Notes, Due January 6, 2030 (Swiss franc-denominated) Fr. 234 1.520% 12-Year Senior Notes, Due January 6, 2037 (Swiss franc-denominated) Fr. 311 1.490% 20-Year Senior Notes, Due January 6, 2045 (Swiss franc-denominated) Fr. 185 1.470% 25-Year Senior Notes, Due January 6, 2050 (Swiss franc-denominated) Fr. 327

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair Value Measurements The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2024. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in bank time deposits, publicly traded securities, insurance contracts, investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration. The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis: December 31, Quoted Significant Significant (In millions) 2024 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,103 $ 1,103 $ — $ — Bank time deposits 1,560 1,560 — — Investments 39 18 — 21 Insurance contracts 240 — 240 — Derivative contracts 460 — 460 — Total assets $ 3,401 $ 2,680 $ 700 $ 21 Liabilities Derivative contracts $ 59 $ — $ 59 $ — Contingent consideration 13 — — 13 Total liabilities $ 72 $ — $ 59 $ 13 December 31, Quoted Significant Significant (In millions) 2023 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 5,021 $ 5,021 $ — $ — Bank time deposits 3 3 — — Investments 20 20 — — Insurance contracts 210 — 210 — Derivative contracts 8 — 8 — Total assets $ 5,262 $ 5,044 $ 218 $ — Liabilities Derivative contracts $ 290 $ — $ 290 $ — Contingent consideration 87 — — 87 Total liabilities $ 377 $ — $ 290 $ 87 The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. (In millions) 2024 2023 Contingent consideration Beginning balance $ 87 $ 174 Acquisitions (including assumed balances) — 1 Payments (2) (63) Changes in fair value included in earnings (73) (25) Ending balance $ 13 $ 87 The following table provides a rollforward of investments classified as level 3: (In millions) 2024 Investments Beginning balance $ — Purchases 21 Ending balance $ 21 Fair Value of Other Financial Instruments The carrying value and fair value of the company’s debt instruments are as follows: December 31, 2024 December 31, 2023 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 30,999 $ 28,454 $ 34,650 $ 32,191 Other 73 73 77 77 $ 31,072 $ 28,527 $ 34,727 $ 32,268

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.20 billion at December 31, 2024, the majority of which are expected to be settled during 2025. Letters of Credit, Guarantees and Other Commitments Outstanding letters of credit and bank guarantees totaled $335 million at December 31, 2024. Substantially all of these letters of credit and guarantees expire before 2040. Outstanding surety bonds and other guarantees totaled $123 million at December 31, 2024. The expiration of these bonds and guarantees ranges through 2028. The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required. The company has funding commitments totaling $182 million at December 31, 2024, related to investments. The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension benefits; however, the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at December 31, 2024 was $25 million. In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in such event, the company would be entitled to seek indemnification from the buyer. Indemnifications In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a liability. Generally, a maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the company has not made significant payments for these indemnifications. In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the facility. As a result, if a third-party vacates the sublet facility, the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by sublessors is individually and in the aggregate not material to the company’s financial position or results of operations. In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The company has not been required to make material payments under such provisions. Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. At December 31, 2024 , the company’s total environmental liability was approximately $81 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows. Litigation and Related Contingencies The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing operations at December 31, 2024, was approximately $224 million to $381 million. The company’s accrual for these matters totaled $225 million at December 31, 2024. The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of $83 million at December 31, 2024 that are included in other assets in the accompanying balance sheet. In addition, as of December 31, 2024, the company had a product liability accrual of $21 million relating to divested businesses.

Supplemental Income Statement I

Supplemental Income Statement Information	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Supplemental Income Statement Information	Supplemental Income Statement Information Disaggregated Revenues Revenues by type are as follows: (In millions) 2024 2023 2022 Revenues Consumables $ 17,587 $ 17,597 $ 20,624 Instruments 7,446 7,646 7,924 Services 17,845 17,614 16,367 Consolidated revenues $ 42,879 $ 42,857 $ 44,915 Revenues by geographic region based on customer location are as follows: (In millions) 2024 2023 2022 Revenues North America $ 22,504 $ 22,764 $ 24,594 Europe 10,857 10,741 10,762 Asia-Pacific 7,956 7,873 8,115 Other regions 1,561 1,479 1,444 Consolidated revenues $ 42,879 $ 42,857 $ 44,915 Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 11 for revenues by reportable segment and other geographic data. Restructuring and Other Costs Restructuring and other costs in 2024 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2024 severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company’s workforce. Restructuring and other costs in 2023 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2023, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the company’s workforce. Restructuring and other costs in 2022 primarily included impairment of long-lived assets and continuing charges for headcount reductions and facility consolidations in an effort to streamline operations. In 2022, severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company’s workforce. As of February 20, 2025, the company has identified restructuring actions, primarily in the Laboratory Products and Biopharma Services segment, that it expects will result in additional charges of approximately $200 million, primarily in 2025, and expects to identify additional actions in future periods. Restructuring and other costs by segment are as follows: (In millions) 2024 2023 2022 Life Sciences Solutions $ 69 $ 105 $ 30 Analytical Instruments 4 33 1 Specialty Diagnostics 17 11 68 Laboratory Products and Biopharma Services 280 295 12 Corporate 9 15 3 $ 379 $ 459 $ 114 The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs (In millions) Total (a) Balance at December 31, 2021 $ 17 Net restructuring charges incurred in 2022 (b) 68 Payments (44) Balance at December 31, 2022 41 Net restructuring charges incurred in 2023 (c) (d) 194 Payments (175) Balance at December 31, 2023 60 Net restructuring charges incurred in 2024 (e) (f) 97 Payments (105) Currency translation (2) Balance at December 31, 2024 $ 50 (a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations. (b) Excludes $46 million of charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment. (c) Excludes $264 million of net charges, principally $126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments, $26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and $19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment. (d) Excludes $93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $46 million attributable to a noncontrolling interest. (e) Excludes $282 million of net charges, principally $211 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments. (f) Excludes $41 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $19 million attributable to a noncontrolling interest. The company expects to pay accrued restructuring costs primarily through 2025. Earnings per Share The company’s earnings per share are as follows: (In millions except per share amounts) 2024 2023 2022 Net income attributable to Thermo Fisher Scientific Inc. $ 6,335 $ 5,995 $ 6,950 Basic weighted average shares 382 386 392 Plus effect of: stock options and restricted stock units 1 2 2 Diluted weighted average shares 383 388 394 Basic earnings per share $ 16.58 $ 15.52 $ 17.75 Diluted earnings per share $ 16.53 $ 15.45 $ 17.63 Antidilutive stock options excluded from diluted weighted average shares 2 2 2 Other Income/(Expense) In all periods, other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities and net periodic pension benefit cost/(income), excluding the service cost component, which is included in operating expenses on the accompanying statements of income. In 2024, 2023, and 2022 other income/(expense) includes $21 million, $(46) million, and $(161) million of net gains/(losses) on investments, respectively. In 2022 other income/(expense) includes $67 million of net gains on derivative instruments to address certain foreign currency risks, and $26 million of losses on the early extinguishment of debt (Note 3). Foreign Currency Transactions Foreign currency transaction gains/(losses) included in the accompanying statements of income were $0 million, $(67) million and $62 million in 2024, 2023 and 2022, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The components of income before provision for income taxes are as follows: (In millions) 2024 2023 2022 U.S. $ 2,226 $ 2,431 $ 3,859 Non-U.S. 4,812 3,867 3,976 Income before income taxes $ 7,037 $ 6,298 $ 7,835 The components of the provision for income taxes are as follows: (In millions) 2024 2023 2022 Current income tax provision Federal $ 561 $ 228 $ 813 Non-U.S. 1,175 1,206 633 State 130 150 254 1,866 1,584 1,700 Deferred income tax provision/(benefit) Federal $ (1,026) $ (551) $ (611) Non-U.S. (72) (647) (314) State (111) (102) (72) (1,209) (1,300) (997) Provision for/(benefit from) income taxes $ 657 $ 284 $ 703 The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following: (In millions) 2024 2023 2022 Statutory federal income tax rate 21 % 21 % 21 % Provision for income taxes at statutory rate $ 1,478 $ 1,323 $ 1,645 Increases (decreases) resulting from: Foreign rate differential (131) (223) (329) Income tax credits (333) (276) (202) Global intangible low-taxed income 57 113 96 Foreign-derived intangible income (133) (108) (149) Excess tax benefits from stock options and restricted stock units (67) (69) (80) Provision for (reversal of) tax reserves, net 218 13 (544) Intra-entity transfers (106) (233) (18) Foreign exchange loss on inter-company debt refinancing — (112) — Provision for (reversal of) valuation allowances, net (229) (32) 344 Withholding taxes 74 33 84 Tax return reassessments and settlements (192) (187) (210) State income taxes, net of federal tax 66 70 111 Other, net (45) (28) (45) Provision for/(benefit from) income taxes $ 657 $ 284 $ 703 The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, non-deductible interest in certain foreign jurisdictions, and foreign taxes that are different than the U.S. federal statutory rate. During 2024, the company recorded a tax reserve and associated interest of $240 million related to the settlement of international tax audits for tax years 2009 through 2016, which were settled in 2024. The company also recorded tax benefits of $459 million, primarily in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income. The benefits were partially offset by tax provisions primarily associated with disallowed interest expense and net operating loss carryforwards that are not expected to be realized. During 2023, the company released valuation allowances of $32 million in jurisdictions where the deferred tax assets are now expected to be realized. In 2023 the company also recorded a tax benefit of $127 million for U.S. tax credits and the revaluation of net operating loss carryforwards due to higher tax rates as a result of its tax return resubmissions, a $91 million tax benefit, net of related tax expenses, from a foreign exchange loss on an intercompany debt refinancing transaction, and $233 million of tax benefits resulting from intra-entity transactions. During 2022, the company settled an IRS audit relating to the 2017 and 2018 tax years. The company recorded a $208 million net tax benefit primarily from this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $658 million. The company recorded $49 million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $395 million to establish a valuation allowance against certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. The company also recorded $101 million of additional net unrecognized tax benefit liabilities related to other tax audits. The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2024, 2023 and 2022, the company's tax provision was reduced by $67 million, $69 million and $80 million, respectively, of such benefits. Net deferred tax asset/(liability) in the accompanying balance sheet consists of the following: (In millions) 2024 2023 Deferred tax asset/(liability) Depreciation and amortization $ (4,133) $ (4,286) Net operating loss and credit carryforwards 2,915 2,385 Reserves and accruals 161 157 Accrued compensation 318 299 Inventory basis difference 309 275 Deferred interest 534 753 Research and development and other capitalized costs 536 380 Unrealized (gains) losses on hedging instruments (363) (66) Contract liabilities 280 130 Other, net 147 199 Deferred tax assets/(liabilities), net before valuation allowance 705 226 Less: Valuation allowance 1,043 1,317 Deferred tax assets/(liabilities), net $ (338) $ (1,091) The company estimates the degree to which tax assets, losses and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2024, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense. The changes in the valuation allowance are as follows: Year Ended December 31, (In millions) 2024 2023 2022 Beginning balance $ 1,317 $ 1,322 $ 968 Additions/(reductions) recognized in income tax provision, net (229) (32) 344 Additions due to acquisitions — 4 14 Currency translation and other (46) 23 (4) Ending balance $ 1,043 $ 1,317 $ 1,322 At December 31, 2024, the company had net federal, state and non-U.S. net operating loss carryforwards of $109 million, $63 million and $1.54 billion, respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. Of the federal net operating loss carryforwards, $43 million expire in the years 2025 through 2037, and the remainder do not expire. Of the state net operating loss carryforwards, $54 million expire in the years 2025 through 2043, and the remainder do not expire. Of the net non-U.S. net operating loss carryforwards, $574 million expire in the years 2027 through 2044, and the remainder do not expire. At December 31, 2024, the company had foreign tax credit carryforwards of $729 million and deferred interest carryforwards of $534 million. The foreign tax credit carryforwards will expire in the years 2025 through 2034. Of the deferred interest carryforwards, $201 million expire in the years 2025 through 2034 and the remainder do not expire. U.S. federal taxes have been recorded on approximately $40 billion of undistributed foreign earnings as of December 31, 2024. A provision has not been made for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost. Unrecognized Tax Benefits As of December 31, 2024, the company had $0.52 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2024 2023 2022 Beginning balance $ 540 $ 572 $ 1,124 Additions due to acquisitions 19 — 15 Additions for tax positions of current year 91 4 104 Additions for tax positions of prior years 244 34 24 Reductions for tax positions of prior years (182) (43) (659) Closure of tax years — (6) (4) Settlements (187) (21) (32) Ending balance $ 525 $ 540 $ 572 Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change significantly over the next twelve months. During 2024, the company’s unrecognized tax benefits decreased by $99 million as a result of uncertain tax positions relating to foreign tax positions which included $240 million of reserve and associated interest from the settlement of international tax audits for tax years 2009 through 2016 and increased $84 million relating to U.S. federal and state tax positions. During 2023, the company’s unrecognized tax benefits decreased by $12 million as a result of uncertain tax positions relating to foreign tax positions and decreased $19 million relating to U.S. federal and state tax positions. During 2022, the company’s unrecognized tax benefits increased by $143 million as a result of uncertain tax positions relating to foreign tax positions and decreased $610 million relating to U.S. federal and state tax positions which included $658 million from the settlement of the IRS audit of the 2017 and 2018 tax years. The company also assumed $15 million of uncertain tax benefits as part of the acquisition of PPD. The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to uncertain tax positions and recognized in the balance sheet as of December 31, 2024 and 2023 was $75 million and $95 million, respectively. The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years before 2012 and no longer subject to U.S. federal income tax examinations for years before 2019.

Comprehensive Income_(Loss) and

Comprehensive Income/(Loss) and Shareholders' Equity	12 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Comprehensive Income/(Loss) and Shareholders' Equity	Comprehensive Income/(Loss) and Shareholders' Equity Comprehensive Income (Loss) Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2023 $ (2,941) $ (28) $ (255) $ (3,224) Other comprehensive income/(loss) before reclassifications 525 — (12) 513 Amounts reclassified from accumulated other comprehensive income/(loss) 7 3 4 14 Net other comprehensive income/(loss) 532 3 (8) 527 Balance at December 31, 2024 $ (2,409) $ (25) $ (263) $ (2,697) Shareholders’ Equity At December 31, 2024, the company had reserved 37 million unissued shares of its common stock for possible issuance under stock-based compensation plans. Early in the first quarter of 2025, the company repurchased $2.00 billion of the company's common stock (3.6 million shares).

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2024
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information Supplemental cash flow information is as follows: (In millions) 2024 2023 2022 Cash paid for: Interest $ 1,570 $ 1,385 $ 667 Income taxes 1,834 1,482 1,234 Non-cash investing and financing activities Acquired but unpaid property, plant and equipment 303 296 393 Finance lease ROU assets obtained in exchange for new finance lease liabilities — 2 33 Declared but unpaid dividends 150 137 119 Issuance of stock upon vesting of restricted stock units 186 234 241 Excise tax from stock repurchases 26 28 — Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: December 31, December 31, (In millions) 2024 2023 Cash and cash equivalents $ 4,009 $ 8,077 Restricted cash included in other current assets 10 6 Restricted cash included in other assets 21 14 Cash, cash equivalents and restricted cash $ 4,040 $ 8,097

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. December 31, December 31, (In millions) 2024 2023 Notional amount Cross-currency interest rate swaps designated as net investment hedge - euro $ 1,000 $ 1,000 Cross-currency interest rate swaps designated as net investment hedge - Japanese yen 4,650 4,650 Cross-currency interest rate swaps designated as net investment hedge - Swiss franc 2,500 2,500 Currency exchange contracts 1,588 1,567 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income. Fair value – assets Fair value – liabilities December 31, December 31, December 31, December 31, (In millions) 2024 2023 2024 2023 Derivatives designated as hedging instruments Cross-currency interest rate swaps $ 458 $ 5 $ 57 $ 287 Derivatives not designated as hedging instruments Currency exchange contracts 2 3 2 3 Total derivatives $ 460 $ 8 $ 59 $ 290 Gain/(loss) recognized (In millions) 2024 2023 2022 Fair value hedging relationships Cross-currency interest rate swaps Hedged long-term obligations - included in other income/(expense) $ — $ — $ 77 Derivatives designated as hedging instruments - included in other income/(expense) — — (81) Derivatives designated as cash flow hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to interest expense (3) (4) — Amount reclassified from accumulated other comprehensive items to other income/(loss) — (3) (3) Financial instruments designated as net investment hedges Foreign currency-denominated debt and other payables Included in currency translation adjustment within other comprehensive income/(loss) 686 (356) 695 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive income/(loss) 682 (222) 52 Included in interest expense 267 120 19 Derivatives not designated as hedging instruments Currency exchange contracts Included in cost of product revenues 21 1 6 Included in other income/(expense) (16) (29) 102 Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statements of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. See Note 1 and Note 3 for additional information on the company’s risk management objectives and strategies.

Business Segment and Geographic

Business Segment and Geographical Information	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Business Segment and Geographical Information	Business Segment and Geographical Information The company’s financial performance is reported in four segments. A description of each segment follows. Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Analytical Instruments: provides a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory. Specialty Diagnostics: offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which improves patient care in a more cost-efficient manner. Laboratory Products and Biopharma Services: offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive and cost-efficient. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, restructuring and other costs, and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation. The company's president, chairman and chief executive officer is its chief operating decision maker (CODM). The CODM uses total revenues and segment income predominantly in the strategic plan, annual operating plan and quarterly business review processes. During these processes, the CODM considers budget-to-actual variances to evaluate both internal (e.g., changes in selling prices, strategic growth investments, productivity, business mix, newly acquired/divested businesses, etc.) and external (e.g., inflation, foreign currency, etc.) events and conditions. The company generally accounts for intersegment revenues at current market prices. Other segment items included in the below tables consist of stock-based compensation and other incentive compensation expenses, allocations of corporate expenses and certain overhead expenses as well as elimination of intersegment and intrasegment profits, all of which are included in the company's measurement of segment income, but not regularly provided to the CODM at the segment level. Cost of revenues adjustments consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the consolidation of operations. Selling, general and administrative adjustments consist of significant transaction/integration costs (including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges related to product liability litigation. Restructuring and other costs include charges arising from headcount reductions and facility consolidations such as severance and abandoned lease expense and gains and losses on the sale of real estate and product lines, as well as impacts of pre-acquisition matters and net charges for significant litigation-related matters (Note 6). Segment assets included in the below tables consist of third-party accounts receivable and inventories, which are regularly provided to the CODM. Geographical revenues are attributed to countries based on customer location. Long-lived assets by geographical location includes property, plant and equipment, net, and operating lease ROU assets. Business Segment Information 2024 (In millions) Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Total Revenues Revenues from external customers $ 8,160 $ 7,267 $ 4,449 $ 23,002 $ 42,879 Intersegment revenues 1,471 196 63 155 1,885 9,631 7,463 4,512 23,157 44,764 Elimination of intersegment revenues (1,885) Consolidated revenues $ 42,879 Segment Income Cost of revenues 3,559 3,535 2,605 18,074 Selling, general, and administrative expenses 1,799 1,251 741 2,378 Research and development expenses 551 554 176 73 Other segment items 219 167 (168) (459) Segment income 3,503 1,955 1,159 3,090 9,707 Unallocated amounts Cost of revenues adjustments (47) Selling, general and administrative expenses adjustments 8 Restructuring and other costs (379) Amortization of acquisition-related intangible assets (1,952) Interest income 1,078 Interest expense (1,390) Other income/(expense) 12 Consolidated income before income taxes $ 7,037 (In millions) Unallocated amounts Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Consolidated Segment assets $ 84,031 $ 2,982 $ 2,944 $ 1,218 $ 6,145 $ 97,321 Purchases of property, plant and equipment 85 123 95 125 971 1,400 Depreciation of property, plant and equipment — 230 103 104 721 1,156 2023 (In millions) Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Total Revenues Revenues from external customers $ 8,545 $ 7,101 $ 4,324 $ 22,888 $ 42,857 Intersegment revenues 1,432 163 82 154 1,829 9,977 7,263 4,405 23,041 44,686 Elimination of intersegment revenues (1,829) Consolidated revenues $ 42,857 Segment Income Cost of revenues 4,072 3,468 2,592 18,033 Selling, general, and administrative expenses 1,791 1,252 724 2,304 Research and development expenses 558 528 156 68 Other segment items 136 107 (191) (722) Segment income 3,420 1,908 1,124 3,358 9,810 Unallocated amounts Cost of revenues adjustments (95) Selling, general and administrative expenses adjustments (59) Restructuring and other costs (459) Amortization of acquisition-related intangible assets (2,338) Interest income 879 Interest expense (1,375) Other income/(expense) (65) Consolidated income before income taxes $ 6,298 (In millions) Unallocated amounts Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Consolidated Segment assets $ 85,314 $ 3,186 $ 2,726 $ 1,150 $ 6,350 $ 98,726 Purchases of property, plant and equipment 80 178 87 121 1,013 1,479 Depreciation of property, plant and equipment — 220 93 86 669 1,068 2022 (In millions) Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Total Revenues Revenues from external customers $ 11,565 $ 6,441 $ 4,604 $ 22,304 $ 44,915 Intersegment revenues 1,967 182 158 207 2,515 13,532 6,624 4,763 22,511 47,430 Elimination of intersegment revenues (2,515) Consolidated revenues $ 44,915 Segment Income Cost of revenues 4,973 3,194 3,095 17,830 Selling, general, and administrative expenses 2,027 1,235 605 2,347 Research and development expenses 680 508 147 85 Other segment items 270 180 (108) (623) Segment income 5,582 1,507 1,024 2,872 10,985 Unallocated amounts Cost of revenues adjustments (46) Selling, general and administrative expenses adjustments (37) Restructuring and other costs (114) Amortization of acquisition-related intangible assets (2,395) Interest income 272 Interest expense (726) Other income/(expense) (104) Consolidated income before income taxes $ 7,835 (In millions) Unallocated amounts Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Consolidated Segment assets $ 83,340 $ 3,845 $ 2,465 $ 1,076 $ 6,428 $ 97,154 Purchases of property, plant and equipment 98 490 140 112 1,403 2,243 Depreciation of property, plant and equipment — 214 83 75 614 986 Geographical Information (In millions) 2024 2023 2022 Revenues United States $ 21,755 $ 22,013 $ 23,820 Other 21,124 20,844 21,095 Consolidated revenues $ 42,879 $ 42,857 $ 44,915 Long-lived Assets United States $ 6,245 $ 6,352 $ 6,308 Other 4,550 4,652 4,565 Consolidated long-lived assets $ 10,795 $ 11,004 $ 10,873

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions	Acquisitions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred. 2024 On July 10, 2024, the company acquired, within the Life Sciences Solutions segment, Olink Holding AB (publ), a Swedish-based provider of next-generation proteomics solutions. The acquisition enhances the segment’s capabilities in the high-growth proteomics market with the addition of highly differentiated solutions. It also complements the existing life sciences and mass spectrometry offerings, accelerating protein biomarker discovery and providing strong synergy opportunities. The goodwill recorded as a result of this business combination is not tax deductible. The components of the purchase price and net assets acquired are as follows: (In millions) Olink Purchase price Cash paid $ 3,215 Purchase price payable 28 Cash acquired (97) $ 3,146 Net assets acquired Definite-lived intangible assets Customer relationships $ 708 Product technology 207 Tradenames 97 Goodwill 2,302 Net tangible assets 8 Deferred tax assets (liabilities) (176) $ 3,146 The weighted-average amortization periods for definite-lived intangible assets acquired in 2024 are 19 years for customer relationships, 15 years for product technology, and 15 years for tradenames. The weighted-average amortization period for definite-lived intangible assets acquired in 2024 is 18 years. 2023 On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business combination is not tax deductible. On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a result of this business combination is not tax deductible. The components of the purchase price and net assets acquired are as follows: (In millions) The Binding Site CorEvitas Purchase price Cash paid $ 2,412 $ 730 Debt settled 307 184 Cash acquired (20) (4) $ 2,699 $ 910 Net assets acquired Definite-lived intangible assets Customer relationships $ 868 $ 260 Product technology 162 47 Tradenames 42 — Backlog — 46 Goodwill 1,741 627 Net tangible assets 174 (2) Deferred tax assets (liabilities) (288) (68) $ 2,699 $ 910 In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-line measurement. The weighted-average amortization periods for definite-lived intangible assets acquired in 2023 are 18 years for customer relationships, 14 years for product technology, 15 years for tradenames, and 13 years for backlog. The weighted-average amortization period for definite-lived intangible assets acquired in 2023 is 17 years. 2022

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year. The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2025, and 2028, and 2029. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 3). The aggregate maximum guarantee under these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of December 31, 2024, but exclude any amounts for residual value guarantees. As a lessee, the consolidated financial statements include the following relating to operating leases: (Dollars in millions) 2024 2023 2022 Statement of income Operating lease costs $ 353 $ 355 $ 351 Variable lease costs 115 115 109 Statement of cash flows Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities $ 327 $ 410 $ 289 Operating lease ROU assets obtained in exchange for new operating lease liabilities 262 234 430 Balance sheet ROU assets - included in other assets $ 1,489 $ 1,556 Operating lease liabilities - included in other accrued expenses 261 263 Operating lease liabilities - included in other long-term liabilities 1,239 1,244 Weighted average at end of year Remaining operating lease term 8.6 years 9.2 years Discount rate 4.6 % 4.0 % Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 3 for additional information relating to finance leases. As of December 31, 2024, future payments of operating lease liabilities are as follows: (In millions) 2025 $ 320 2026 277 2027 235 2028 167 2029 136 2030 and thereafter 723 Total lease payments 1,858 Less: imputed interest 357 Total operating lease liability $ 1,501 As a lessor, operating leases, sales-type leases and direct financing leases are not material.

Pension and Other Postretiremen

Pension and Other Postretirement Benefit Plans	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefit Plans	Pension and Other Postretirement Benefit Plans 401(k) Savings Plan and Other Defined Contribution Plans The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees. Contributions to the plans are made by both employees and the company. Company contributions are based on the level of employee contributions and formulas determined by the company. In 2024, 2023 and 2022, the company charged to expense $443 million, $468 million and $402 million, respectively, related to its defined contribution plans. Defined Benefit Pension Plans Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented. Contributions to the plans included in the following table are estimated at between $40 million and $50 million for 2025. The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans: Domestic pension benefits Non-U.S. pension benefits (In millions) 2024 2023 2024 2023 Accumulated benefit obligation $ 937 $ 1,005 $ 1,079 $ 1,166 Change in projected benefit obligations Projected benefit obligation at beginning of year $ 1,005 $ 995 $ 1,221 $ 1,069 Acquisitions — — — 15 Service costs — — 28 26 Interest costs 46 47 40 42 Settlements — — (29) (37) Plan participants' contributions — — 10 9 Actuarial (gains)/losses (32) 42 (59) 65 Benefits paid (81) (79) (26) (25) Currency translation and other — — (49) 57 Projected benefit obligation at end of year $ 937 $ 1,005 $ 1,135 $ 1,221 Change in fair value of plan assets Fair value of plan assets at beginning of year $ 947 $ 937 $ 944 $ 868 Acquisitions — — — 15 Actual return on plan assets 22 84 (37) 29 Employer contributions 7 5 37 36 Settlements — — (29) (37) Plan participants' contributions — — 10 9 Benefits paid (81) (79) (26) (25) Currency translation and other — — (32) 49 Fair value of plan assets at end of year $ 895 $ 947 $ 867 $ 944 Funded status $ (43) $ (58) $ (268) $ (277) Amounts recognized in balance sheet Noncurrent assets $ 5 $ — $ 57 $ 65 Current liability (5) (6) (12) (11) Noncurrent liabilities (42) (52) (313) (331) Net amount recognized $ (43) $ (58) $ (268) $ (277) Amounts recognized in accumulated other comprehensive items Net actuarial loss/(gain) $ 218 $ 217 $ 156 $ 151 Prior service (credits)/cost — — (7) (5) Net amount recognized $ 218 $ 217 $ 149 $ 146 Actuarial (gains)/losses experienced in 2024 for both domestic and non-U.S. pension plans were primarily driven by increases in the weighted average discount rates used to determine the projected benefit obligation when compared to 2023. For domestic pension plans, actuarial (gains)/losses experienced in 2023 were driven by decreases in the weighted average discount rates used to determine the projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset returns. For non-U.S. pension plans, actuarial (gains)/losses experienced in 2023 were principally driven by decreases in the weighted average discount rates used to determine the projected benefit obligation. The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2024 and 2023 and are as follows: Domestic pension benefits Non-U.S. pension benefits 2024 2023 2024 2023 Weighted average assumptions used to determine projected benefit obligations Discount rate for determining benefit obligation 5.48 % 4.82 % 3.74 % 3.47 % Interest crediting rate for cash balance plans 5.39 % 4.76 % 2.28 % 2.06 % Average rate of increase in employee compensation N/A N/A 2.58 % 2.64 % The actuarial assumptions used to compute the net periodic pension benefit cost/(income) are based upon information available as of the beginning of the year, as presented in the following table: Domestic pension benefits Non-U.S. pension benefits 2024 2023 2022 2024 2023 2022 Weighted average assumptions used to determine net benefit cost/(income) Discount rate - service cost N/A N/A N/A 3.00 % 3.62 % 1.00 % Discount rate - interest cost 4.82 % 5.01 % 2.70 % 3.48 % 3.95 % 1.36 % Interest crediting rate for cash balance plans 4.76 % 4.96 % 2.58 % 2.06 % 2.19 % 1.25 % Average rate of increase in employee compensation N/A N/A N/A 2.64 % 2.77 % 2.73 % Expected long-term rate of return on assets 6.00 % 6.25 % 4.75 % 4.28 % 4.33 % 2.33 % The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows: Pension plans (In millions) 2024 2023 Pension plans with projected benefit obligations in excess of plan assets Projected benefit obligation $ 727 $ 1,752 Fair value of plan assets 376 1,352 The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows: Pension plans (In millions) 2024 2023 Pension plans with accumulated benefit obligations in excess of plan assets Accumulated benefit obligation $ 671 $ 1,695 Fair value of plan assets 376 1,349 The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations. The net periodic pension benefit cost/(income) includes the following components: Domestic pension benefits Non-U.S. pension benefits (In millions) 2024 2023 2022 2024 2023 2022 Components of net benefit cost/(income) Service cost $ — $ — $ — $ 28 $ 26 $ 34 Interest cost on benefit obligation 46 47 27 40 42 20 Expected return on plan assets (56) (59) (45) (36) (37) (26) Amortization of actuarial net loss — — 4 4 2 7 Amortization of prior service cost/(benefit) — — — (1) (1) (1) Settlement/curtailment loss/(gain) — — — 2 1 (2) Net periodic benefit cost/(income) $ (10) $ (12) $ (14) $ 38 $ 33 $ 32 Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2024. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows: (In millions) Domestic pension benefits Non-U.S. pension benefits Expected benefit payments 2025 $ 82 $ 54 2026 81 57 2027 81 58 2028 80 62 2029 79 66 2030-2034 373 405 Domestic Pension Plan Assets The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments. Non-U.S. Pension Plan Assets The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative investments, real estate funds and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 40% for multi-asset funds, 0% - 4% for alternative investments, 0% - 4% for real estate funds and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments. The fair values of the company’s plan assets at December 31, 2024 and 2023, by asset category are as follows: December 31, Quoted Significant Significant Not subject to leveling (a) (In millions) 2024 (Level 1) (Level 2) (Level 3) Domestic pension plan assets U.S. equity funds $ 91 $ — $ — $ — $ 91 International equity funds 89 — — — 89 Fixed income funds 692 — — — 692 Money market funds 23 — — — 23 Total domestic pension plans $ 895 $ — $ — $ — $ 895 Non-U.S. pension plan assets Equity funds $ 7 $ — $ — $ — $ 7 Fixed income funds 288 7 — — 281 Multi-asset funds 69 — — — 69 Derivative funds 169 — — — 169 Insurance contracts 325 — 325 — — Cash / money market funds 9 4 — — 5 Total non-U.S. pension plans $ 867 $ 10 $ 325 $ — $ 532 (a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. December 31, Quoted Significant Significant Not subject to leveling (a) (In millions) 2023 (Level 1) (Level 2) (Level 3) Domestic pension plan assets U.S. equity funds $ 93 $ — $ — $ — $ 93 International equity funds 93 — — — 93 Fixed income funds 739 — — — 739 Money market funds 22 — — — 22 Total domestic pension plans $ 947 $ — $ — $ — $ 947 Non-U.S. pension plan assets Equity funds $ 7 $ — $ — $ — $ 7 Fixed income funds 346 9 — — 337 Multi-asset funds 66 — — — 66 Derivative funds 184 — — — 184 Alternative investments 1 — — — 1 Insurance contracts 333 — 333 — — Real estate funds 1 — — — 1 Cash / money market funds 6 4 — — 2 Total non-U.S. pension plans $ 944 $ 13 $ 333 $ — $ 598 (a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 1). Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.

Stock-based Compensation Expens

Stock-based Compensation Expense	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation Expense	Stock-based Compensation Expense The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s Board of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides for different treatment). Stock Options The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 2024 2023 2022 Expected stock price volatility 25 % 25 % 26 % Risk free interest rate 4.3 % 4.2 % 2.0 % Expected life of options (years) 5.0 4.7 4.7 Expected annual dividend 0.3 % 0.3 % 0.2 % Weighted average per share grant-date fair values of options granted $ 166.92 $ 159.32 $ 135.07 The total intrinsic value of options exercised during the same periods was $395 million, $320 million and $336 million, respectively. The intrinsic value is the difference between the market value of the shares on the exercise date and the exercise price of the option. A summary of the company’s option activity for the year ended December 31, 2024 is presented below: Shares Weighted average exercise price Weighted average remaining contractual term Aggregate intrinsic Outstanding at December 31, 2023 5.0 $ 401.30 Granted 1.0 554.31 Exercised (1.2) 260.55 Canceled/expired (0.2) 559.45 Outstanding at December 31, 2024 4.5 $ 465.80 4.3 $ 358 Vested and unvested expected to vest at December 31, 2024 4.4 $ 462.90 4.2 $ 358 Exercisable at December 31, 2024 2.6 $ 403.06 2.9 $ 350 As of December 31, 2024, there was $176 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2028 with a weighted average amortization period of 2.1 years. Restricted Share/Unit Awards A summary of the company’s restricted unit activity for the year ended December 31, 2024 is presented below: Units Weighted Unvested at December 31, 2023 0.6 $ 533.65 Granted 0.4 556.83 Performance adjustments (0.1) 558.66 Vested (0.3) 524.55 Forfeited (0.1) 539.83 Unvested at December 31, 2024 0.6 $ 551.81 The weighted average per share grant-date fair values of restricted units granted during 2023 and 2022 were $545.73 and $520.83, respectively. The total fair value of shares vested during 2024, 2023 and 2022 was $165 million, $207 million and $163 million, respectively. As of December 31, 2024, there was $225 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2028 with a weighted average amortization period of 1.9 years. Employee Stock Purchase Plans Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through payroll deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.1 million, 0.1 million and 0.2 million shares, respectively, of its common stock in 2024, 2023 and 2022 under the employee stock purchase plan.

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Dec. 31, 2024 shares	Dec. 31, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Michael A. Boxer [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On December 5, 2024, Michael A. Boxer, our senior vice president, general counsel, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Boxer’s plan is for the exercise of vested stock options and the associated sale of up to 7,450 shares of company common stock through June 11, 2025. The foregoing exercises and sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and June 11, 2025.
Name	Michael A. Boxer
Title	senior vice president, general counsel
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 5, 2024
Expiration Date	June 11, 2025
Arrangement Duration	188 days
Aggregate Available	7,450	7,450
Michael D. Shafer [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On November 20, 2024, Michael D. Shafer, an executive vice president, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Shafer’s plan is for the sale of up to 2,509 shares of company stock, and the exercise of vested stock options and the associated sale of up to 10,725 shares of company common stock, through December 12, 2025. The foregoing exercises and sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 15, 2025.
Name	Michael D. Shafer
Title	executive vice president
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	November 20, 2024
Expiration Date	December 15, 2025
Arrangement Duration	387 days
Michael D. Shafer Trading Arrangement, Common Stock [Member] | Michael D. Shafer [Member]
Trading Arrangements, by Individual
Aggregate Available	2,509	2,509
Michael D. Shafer Trading Arrangement, Vested Stock Options [Member] | Michael D. Shafer [Member]
Trading Arrangements, by Individual
Aggregate Available	10,725	10,725

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Cybersecurity Risk Management and Strategy As is the case for most large global companies, we are regularly subject to cyberattacks and other cybersecurity incidents and, therefore, we incorporate cybersecurity into our overall risk management process. Our commitment to cybersecurity emphasizes using a risk-based, “defense in depth” approach to assess, educate, block, identify, respond to and recover from cybersecurity threats. Recognizing that no single technology, process or control can effectively prevent or mitigate all risks, we employ a strategy of technologies, processes and controls, all working independently but as part of a cohesive strategy to manage or reduce risk. Our cybersecurity program assists in the management of risks associated with the confidentiality, integrity and availability of data and systems within the company environment to effectively support our business objectives and customer expectations. The program provides guidance to business stakeholders on cybersecurity risks as input into their risk management processes that balance cybersecurity risk with other important risks that may include strategic, regulatory, economic and financial considerations. We seek to routinely refine our cybersecurity approach to adapt to changes in the threat landscape and manage emerging security risks. In order to evaluate risks from cybersecurity threats associated with the company’s use of certain third-party technology providers, we have incorporated a risk-based assessment into the corporate information technology (IT) procurement process designed to assess the security risk of certain third parties providing new technology solutions to our environment. We believe cybersecurity is the responsibility of every employee, and regularly educate and share best practices with our employees to raise awareness of cybersecurity threats through a security awareness training program, including regular exercises, periodic cyber-event simulations and annual attestation to our Technology Acceptable Use Policy.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Cybersecurity is integrated into the risk management process for the company through various corporate mechanisms, including quarterly business reviews, annual budget planning, and targeted risk-based engagements.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	The Board of Directors has delegated the oversight of cybersecurity risks to the Audit Committee. Our cybersecurity program is led by the company’s senior vice president, chief information officer, along with our vice president, chief information security officer (CISO). Management provides an operational update to the Audit Committee each quarter. In addition, the Audit Committee and our full Board of Directors receive an annual overview of the cybersecurity program, cybersecurity threat landscape, investments, and opportunities to enhance the company’s systems and security of products and operations.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board of Directors has delegated the oversight of cybersecurity risks to the Audit Committee.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Management provides an operational update to the Audit Committee each quarter.
Cybersecurity Risk Role of Management [Text Block]	Management provides an operational update to the Audit Committee each quarter. In addition, the Audit Committee and our full Board of Directors receive an annual overview of the cybersecurity program, cybersecurity threat landscape, investments, and opportunities to enhance the company’s systems and security of products and operations.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	The Board of Directors has delegated the oversight of cybersecurity risks to the Audit Committee. Our cybersecurity program is led by the company’s senior vice president, chief information officer, along with our vice president, chief information security officer (CISO). Management provides an operational update to the Audit Committee each quarter. In addition, the Audit Committee and our full Board of Directors receive an annual overview of the cybersecurity program, cybersecurity threat landscape, investments, and opportunities to enhance the company’s systems and security of products and operations.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our senior vice president, chief information officer, vice president, CISO, and vice president, chief product security officer have each served in various roles in IT and information security for over 20 years. These individuals’ knowledge and experience along with the culture and talent of the corporate IT security team organization are instrumental in developing and executing our cybersecurity strategies.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Management provides an operational update to the Audit Committee each quarter.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation and Redeemable Noncontrolling Interest	Principles of Consolidation The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany accounts and transactions have been eliminated. Redeemable Noncontrolling Interest The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the remaining ownership interest at a premium upon the occurrence of certain events.
Presentation	Presentation Certain reclassifications of prior year amounts have been made to conform to the current year presentation. Amounts and percentages reported within these consolidated financial statements are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash equivalents consists principally of money market funds and other marketable securities purchased with a remaining maturity of three months or less. These investments are carried at cost, which approximates market value (see Note 4).
Inventories	Inventories
Contract-related Balances	Contract-related Balances Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions, expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Revenue Recognition	Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration becomes unconditional. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance obligations in the same contract. Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet, respectively (see Note 2). Revenue Recognition Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. However, some modifications are distinct from existing services provided under the contract and recognized prospectively. Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g., pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.
Property, Plant and Equipment	Property, Plant and Equipment
Acquisition-related Intangible Assets	Acquisition-related Intangible Assets Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted cash flows. In these situations, the carrying value is written down to fair value.
Investments	Investments Investments include marketable securities, such as marketable equity securities, available for sale debt securities, and bank time deposits with maturities greater than three months, equity method investments, and non-marketable equity investments. The company classifies investments as current or noncurrent based on the nature of the securities and their availability for use in current operations. Noncurrent investments are included in other assets. Marketable securities are stated at fair value with all realized and unrealized gains and losses on investments in marketable equity securities and realized gains and losses on available-for-sale debt securities recognized in other income/(expense).
Goodwill	Goodwill The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the quantitative goodwill impairment test. The company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in 2024, 2023 or 2022.
Fair Value Measurements	Fair Value Measurements Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves. Level 3: Inputs are unobservable data points that are not corroborated by market data.
Loss Contingencies	Loss Contingencies Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites.
Warranty Obligations	Warranty Obligations
Foreign Currency Translation	Foreign Currency Translation All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average exchange rates for the period.
Research and Development	Research and Development The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and development costs are expensed as incurred.
Restructuring Costs	Restructuring Costs Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such benefits, (c) the termination benefits are due to the occurrence of an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models. From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs, that are not associated with or will not be incurred to provide economic benefits to the company. These include costs that represent amounts under contractual obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the original contractual period.
Earnings per Share	Earnings per Share Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share has been computed using the treasury stock method for outstanding stock options and restricted units (see Note 6).
Income Taxes	Income Taxes The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A valuation allowance is provided for tax assets that will more likely than not go unused. The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money (see Note 7).
Derivatives Contracts	Derivative Contracts The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings. The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, Canadian dollars, British pounds sterling, Swedish krona, Singapore dollars, Hong Kong dollars and Swiss franc. The company does not hold or engage in transactions involving derivative instruments for purposes other than risk management. Cash flow hedges . For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings and is presented in the same income statement line item as the earnings effect of the hedged item. Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings. Net investment hedges. The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
Leases	Leases Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations. Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-line basis over the expected life of the leased asset, and an immaterial amount of interest expense. Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option.
Pension and Other Postretirement Benefit Plans	Pension and Other Postretirement Benefit Plans The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net periodic benefit cost/(income). Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost/(income). When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a) previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits. The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. The discount rate used to determine projected benefit obligations and net periodic pension benefit cost/(income) reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan. The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the determination of the benefit obligation to the relevant projected cash flows. The expected long-term rate of return on plan assets used to determine net periodic pension benefit cost/(income) reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks. Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirements. The expected rate of compensation increase used to determine net periodic pension benefit cost/(income) reflects the long-term average rate of salary increases and is based on historic salary increase experience and management’s expectations of future salary increases (see Note 14). Defined Benefit Pension Plans Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented. Domestic Pension Plan Assets The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility. The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80% to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments. Non-U.S. Pension Plan Assets The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds, multi-asset funds, alternative investments, real estate funds and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% - 90% for fixed income funds, 0% - 40% for multi-asset funds, 0% - 4% for alternative investments, 0% - 4% for real estate funds and 0% - 45% for funds holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan maintains enough liquidity at all times to meet the near-term benefit payments.
Stock-based Compensation Expense	Stock-based Compensation Expense Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility, if earlier, and is primarily included in selling, general and administrative expenses. The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The expected annual dividend rate is calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures. Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award, which is generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date. For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award (see Note 15).
Government Assistance	Government Assistance From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement. Such amounts were not material to the consolidated financial statements as of and for the years ended December 31, 2024, 2023 and 2022.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures. Standard Description Effective date for Thermo Fisher and adoption approach Impact of adoption or other significant matters Standards recently adopted ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance New guidance to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. Fourth quarter of 2022 using a prospective method Not material ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented. Some aspects adopted in 2023 using a retrospective method and other aspects adopted in 2024 using a prospective method Not material ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker. 2024 annual report and interim periods thereafter using a retrospective method Increased disclosures in Note 11 Standards not yet adopted ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid. 2025 annual report and interim periods thereafter using a prospective or retrospective method Will increase disclosures in Note 7 ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses New guidance to disclose specified information about certain costs and expenses. 2027 annual report and interim periods thereafter using a prospective or retrospective method Will increase disclosures in Note 6
Business Combinations	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Recent Accounting Pronouncements	The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures. Standard Description Effective date for Thermo Fisher and adoption approach Impact of adoption or other significant matters Standards recently adopted ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance New guidance to disclose information about certain types of government assistance they receive, including cash grants and tax credits. Among other things, the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. Fourth quarter of 2022 using a prospective method Not material ASU No. 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations New guidance to disclose information about supplier finance programs. Among other things, the new guidance requires expanded disclosure about key program terms, payment terms, and amounts outstanding for obligations under supplier finance programs for each period presented. Some aspects adopted in 2023 using a retrospective method and other aspects adopted in 2024 using a prospective method Not material ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures Among other things, new guidance to disclose significant segment expenses and other items by reportable segment as well as information about the chief operating decision maker. 2024 annual report and interim periods thereafter using a retrospective method Increased disclosures in Note 11 Standards not yet adopted ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid. 2025 annual report and interim periods thereafter using a prospective or retrospective method Will increase disclosures in Note 7 ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses New guidance to disclose specified information about certain costs and expenses. 2027 annual report and interim periods thereafter using a prospective or retrospective method Will increase disclosures in Note 6

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Components of Inventories	The components of inventories are as follows: (In millions) December 31, 2024 December 31, 2023 Raw materials $ 1,803 $ 2,057 Work in process 755 705 Finished goods 2,420 2,326 Inventories $ 4,978 $ 5,088
Schedule of Contract Asset and Liability Balances	Contract asset and liability balances are as follows: (In millions) December 31, 2024 December 31, 2023 Current contract assets, net $ 1,435 $ 1,443 Noncurrent contract assets, net 6 4 Current contract liabilities 2,852 2,689 Noncurrent contract liabilities 1,138 1,499
Schedule of Property, Plant and Equipment	Property, plant and equipment consists of the following: (In millions) December 31, 2024 December 31, 2023 Land $ 439 $ 458 Buildings and improvements 3,728 3,593 Machinery, equipment and leasehold improvements 9,858 9,235 Construction in progress 2,034 2,238 Property, plant and equipment, at cost 16,059 15,524 Less: Accumulated depreciation and amortization 6,753 6,076 Property, plant and equipment, net $ 9,306 $ 9,448
Schedule of Acquisition-related Intangible Assets	Acquisition-related intangible assets are as follows: Balance at December 31, 2024 Balance at December 31, 2023 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite lived: Customer relationships $ 22,644 $ (10,047) $ 12,596 $ 22,762 $ (9,410) $ 13,352 Product technology 5,557 (4,423) 1,134 5,894 (4,591) 1,303 Tradenames 1,706 (1,180) 527 1,634 (1,079) 555 Backlog 1,084 (1,043) 41 1,084 (859) 225 30,991 (16,693) 14,298 31,374 (15,939) 15,435 Indefinite lived: Tradenames 1,235 N/A 1,235 1,235 N/A 1,235 Acquisition-related intangible assets $ 32,226 $ (16,693) $ 15,533 $ 32,609 $ (15,939) $ 16,670
Schedule of Indefinite-Lived Acquisition-related Intangible Assets	Acquisition-related intangible assets are as follows: Balance at December 31, 2024 Balance at December 31, 2023 (In millions) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Definite lived: Customer relationships $ 22,644 $ (10,047) $ 12,596 $ 22,762 $ (9,410) $ 13,352 Product technology 5,557 (4,423) 1,134 5,894 (4,591) 1,303 Tradenames 1,706 (1,180) 527 1,634 (1,079) 555 Backlog 1,084 (1,043) 41 1,084 (859) 225 30,991 (16,693) 14,298 31,374 (15,939) 15,435 Indefinite lived: Tradenames 1,235 N/A 1,235 1,235 N/A 1,235 Acquisition-related intangible assets $ 32,226 $ (16,693) $ 15,533 $ 32,609 $ (15,939) $ 16,670
Schedule of Future Amortization Expense	The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2024 is as follows: (In millions) 2025 $ 1,665 2026 1,496 2027 1,467 2028 1,436 2029 1,324 2030 and thereafter 6,911 Estimated future amortization expense of definite-lived intangible assets $ 14,298
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill by segment are as follows: (In millions) Life Sciences Analytical Specialty Laboratory Total Balance at December 31, 2022 $ 10,146 $ 4,965 $ 3,091 $ 22,994 $ 41,196 Acquisitions — 31 1,741 627 2,399 Currency translation 5 55 91 274 425 Balance at December 31, 2023 10,151 5,051 4,923 23,895 44,020 Acquisitions 2,302 — — — 2,302 Currency translation (117) (92) (139) (122) (470) Balance at December 31, 2024 $ 12,336 $ 4,959 $ 4,784 $ 23,773 $ 45,853

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of Debt	The company’s debt and other financing arrangements are as follows: Effective interest rate at December 31, December 31, December 31, (Dollars in millions) 2024 2024 2023 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) $ — $ 1,104 1.215% 3-Year Senior Notes, Due 10/18/2024 — 2,500 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.40 % 828 883 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.07 % 663 706 0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated) 1.05 % 142 158 0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) 0.14 % 569 607 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) 3.38 % 518 552 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.52 % 725 773 4.953% 3-Year Senior Notes, Due 8/10/2026 5.18 % 600 600 5.000% 3-Year Senior Notes, Due 12/5/2026 5.26 % 1,000 1,000 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.64 % 518 552 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.96 % 621 662 1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated) 1.18 % 184 205 4.80% 5-Year Senior Notes, Due 11/21/2027 5.00 % 600 600 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.76 % 828 883 1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated) 1.79 % 364 — 0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated) 0.90 % 184 206 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 621 662 1.750% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 700 5.000% 5-Year Senior Notes Due 1/31/2029 5.24 % 1,000 1,000 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.07 % 725 773 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated) 1.44 % 30 33 4.977% 7-Year Senior Notes, Due 8/10/2030 5.12 % 750 750 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 0.88 % 1,812 1,932 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 932 993 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 1,200 1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated) 1.92 % 457 — 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.54 % 621 662 Effective interest rate at December 31, December 31, December 31, (Dollars in millions) 2024 2024 2023 1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated) 1.60 % 40 45 4.95% 10-Year Senior Notes, Due 11/21/2032 5.09 % 600 600 5.086% 10-Year Senior Notes, Due 8/10/2033 5.20 % 1,000 1,000 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 1.20 % 1,553 1,656 5.200% 10-Year Senior Notes, Due 1/31/2034 5.34 % 500 500 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) 3.76 % 777 828 1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated) 1.58 % 137 152 2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated) 2.10 % 358 — 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 725 773 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 932 993 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 1,200 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 1.76 % 1,294 1,380 2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated) 2.13 % 93 104 5.404% 20-Year Senior Notes, Due 8/10/2043 5.50 % 600 600 2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated) 2.06 % 184 206 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,035 1,104 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 2.06 % 777 828 2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated) 2.43 % 212 236 Other 73 77 Total borrowings at par value 31,332 35,028 Unamortized discount (95) (113) Unamortized debt issuance costs (164) (188) Total borrowings at carrying value 31,072 34,727 Finance lease liabilities 202 190 Less: Short-term obligations and current maturities 2,214 3,609 Long-term obligations $ 29,061 $ 31,308 In the first quarter of 2025 the company issued the following senior notes: (In millions) Principal Value Issued 0.790% 3-Year Senior Notes, Due January 6, 2028 (Swiss franc-denominated) Fr. 88 1.120% 5-Year Senior Notes, Due January 6, 2030 (Swiss franc-denominated) Fr. 234 1.520% 12-Year Senior Notes, Due January 6, 2037 (Swiss franc-denominated) Fr. 311 1.490% 20-Year Senior Notes, Due January 6, 2045 (Swiss franc-denominated) Fr. 185 1.470% 25-Year Senior Notes, Due January 6, 2050 (Swiss franc-denominated) Fr. 327
Schedule of Annual Repayment Requirements for Debt Obligations	As of December 31, 2024, the annual repayment requirements for debt obligations are as follows: (In millions) Borrowings Finance Lease Liabilities 2025 $ 2,202 $ 12 2026 2,843 12 2027 1,923 10 2028 2,726 9 2029 2,655 8 2030 and thereafter 18,983 151 $ 31,332 $ 202

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Information About the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis: December 31, Quoted Significant Significant (In millions) 2024 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 1,103 $ 1,103 $ — $ — Bank time deposits 1,560 1,560 — — Investments 39 18 — 21 Insurance contracts 240 — 240 — Derivative contracts 460 — 460 — Total assets $ 3,401 $ 2,680 $ 700 $ 21 Liabilities Derivative contracts $ 59 $ — $ 59 $ — Contingent consideration 13 — — 13 Total liabilities $ 72 $ — $ 59 $ 13 December 31, Quoted Significant Significant (In millions) 2023 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 5,021 $ 5,021 $ — $ — Bank time deposits 3 3 — — Investments 20 20 — — Insurance contracts 210 — 210 — Derivative contracts 8 — 8 — Total assets $ 5,262 $ 5,044 $ 218 $ — Liabilities Derivative contracts $ 290 $ — $ 290 $ — Contingent consideration 87 — — 87 Total liabilities $ 377 $ — $ 290 $ 87
Schedule of Fair Value of Investments	The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration. (In millions) 2024 2023 Contingent consideration Beginning balance $ 87 $ 174 Acquisitions (including assumed balances) — 1 Payments (2) (63) Changes in fair value included in earnings (73) (25) Ending balance $ 13 $ 87 The following table provides a rollforward of investments classified as level 3: (In millions) 2024 Investments Beginning balance $ — Purchases 21 Ending balance $ 21
Schedule of the Fair Value of the Company's Debt Instruments	The carrying value and fair value of the company’s debt instruments are as follows: December 31, 2024 December 31, 2023 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 30,999 $ 28,454 $ 34,650 $ 32,191 Other 73 73 77 77 $ 31,072 $ 28,527 $ 34,727 $ 32,268
Schedule of Carrying Value and Fair Value of the Company's Debt Instruments	The carrying value and fair value of the company’s debt instruments are as follows: December 31, 2024 December 31, 2023 Carrying Fair Carrying Fair (In millions) value value value value Senior notes $ 30,999 $ 28,454 $ 34,650 $ 32,191 Other 73 73 77 77 $ 31,072 $ 28,527 $ 34,727 $ 32,268

Supplemental Income Statement_2

Supplemental Income Statement Information (Tables)	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregated Revenues	Revenues by type are as follows: (In millions) 2024 2023 2022 Revenues Consumables $ 17,587 $ 17,597 $ 20,624 Instruments 7,446 7,646 7,924 Services 17,845 17,614 16,367 Consolidated revenues $ 42,879 $ 42,857 $ 44,915 Revenues by geographic region based on customer location are as follows: (In millions) 2024 2023 2022 Revenues North America $ 22,504 $ 22,764 $ 24,594 Europe 10,857 10,741 10,762 Asia-Pacific 7,956 7,873 8,115 Other regions 1,561 1,479 1,444 Consolidated revenues $ 42,879 $ 42,857 $ 44,915
Schedule of Restructuring and Other Costs by Segment	Restructuring and other costs by segment are as follows: (In millions) 2024 2023 2022 Life Sciences Solutions $ 69 $ 105 $ 30 Analytical Instruments 4 33 1 Specialty Diagnostics 17 11 68 Laboratory Products and Biopharma Services 280 295 12 Corporate 9 15 3 $ 379 $ 459 $ 114
Schedule of Changes in the Company's Accrued Restructuring Balance	The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs (In millions) Total (a) Balance at December 31, 2021 $ 17 Net restructuring charges incurred in 2022 (b) 68 Payments (44) Balance at December 31, 2022 41 Net restructuring charges incurred in 2023 (c) (d) 194 Payments (175) Balance at December 31, 2023 60 Net restructuring charges incurred in 2024 (e) (f) 97 Payments (105) Currency translation (2) Balance at December 31, 2024 $ 50 (a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations. (b) Excludes $46 million of charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment. (c) Excludes $264 million of net charges, principally $126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments, $26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and $19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment. (d) Excludes $93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $46 million attributable to a noncontrolling interest. (e) Excludes $282 million of net charges, principally $211 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life Sciences Solutions segments. (f) Excludes $41 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $19 million attributable to a noncontrolling interest.
Schedule of Earnings Per Share	The company’s earnings per share are as follows: (In millions except per share amounts) 2024 2023 2022 Net income attributable to Thermo Fisher Scientific Inc. $ 6,335 $ 5,995 $ 6,950 Basic weighted average shares 382 386 392 Plus effect of: stock options and restricted stock units 1 2 2 Diluted weighted average shares 383 388 394 Basic earnings per share $ 16.58 $ 15.52 $ 17.75 Diluted earnings per share $ 16.53 $ 15.45 $ 17.63 Antidilutive stock options excluded from diluted weighted average shares 2 2 2

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Components of Income Before Provision for Income Taxes	The components of income before provision for income taxes are as follows: (In millions) 2024 2023 2022 U.S. $ 2,226 $ 2,431 $ 3,859 Non-U.S. 4,812 3,867 3,976 Income before income taxes $ 7,037 $ 6,298 $ 7,835
Schedule of Components of the Provision for Income Taxes	The components of the provision for income taxes are as follows: (In millions) 2024 2023 2022 Current income tax provision Federal $ 561 $ 228 $ 813 Non-U.S. 1,175 1,206 633 State 130 150 254 1,866 1,584 1,700 Deferred income tax provision/(benefit) Federal $ (1,026) $ (551) $ (611) Non-U.S. (72) (647) (314) State (111) (102) (72) (1,209) (1,300) (997) Provision for/(benefit from) income taxes $ 657 $ 284 $ 703
Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income taxes due to the following: (In millions) 2024 2023 2022 Statutory federal income tax rate 21 % 21 % 21 % Provision for income taxes at statutory rate $ 1,478 $ 1,323 $ 1,645 Increases (decreases) resulting from: Foreign rate differential (131) (223) (329) Income tax credits (333) (276) (202) Global intangible low-taxed income 57 113 96 Foreign-derived intangible income (133) (108) (149) Excess tax benefits from stock options and restricted stock units (67) (69) (80) Provision for (reversal of) tax reserves, net 218 13 (544) Intra-entity transfers (106) (233) (18) Foreign exchange loss on inter-company debt refinancing — (112) — Provision for (reversal of) valuation allowances, net (229) (32) 344 Withholding taxes 74 33 84 Tax return reassessments and settlements (192) (187) (210) State income taxes, net of federal tax 66 70 111 Other, net (45) (28) (45) Provision for/(benefit from) income taxes $ 657 $ 284 $ 703
Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance	Net deferred tax asset/(liability) in the accompanying balance sheet consists of the following: (In millions) 2024 2023 Deferred tax asset/(liability) Depreciation and amortization $ (4,133) $ (4,286) Net operating loss and credit carryforwards 2,915 2,385 Reserves and accruals 161 157 Accrued compensation 318 299 Inventory basis difference 309 275 Deferred interest 534 753 Research and development and other capitalized costs 536 380 Unrealized (gains) losses on hedging instruments (363) (66) Contract liabilities 280 130 Other, net 147 199 Deferred tax assets/(liabilities), net before valuation allowance 705 226 Less: Valuation allowance 1,043 1,317 Deferred tax assets/(liabilities), net $ (338) $ (1,091) The company estimates the degree to which tax assets, losses and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31, 2024, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for which any subsequently recognized tax benefits will reduce income tax expense. The changes in the valuation allowance are as follows: Year Ended December 31, (In millions) 2024 2023 2022 Beginning balance $ 1,317 $ 1,322 $ 968 Additions/(reductions) recognized in income tax provision, net (229) (32) 344 Additions due to acquisitions — 4 14 Currency translation and other (46) 23 (4) Ending balance $ 1,043 $ 1,317 $ 1,322
Schedule of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2024 2023 2022 Beginning balance $ 540 $ 572 $ 1,124 Additions due to acquisitions 19 — 15 Additions for tax positions of current year 91 4 104 Additions for tax positions of prior years 244 34 24 Reductions for tax positions of prior years (182) (43) (659) Closure of tax years — (6) (4) Settlements (187) (21) (32) Ending balance $ 525 $ 540 $ 572

Comprehensive Income_(Loss) a_2

Comprehensive Income/(Loss) and Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Schedule of Changes in Each Component of Accumulated Other Comprehensive Items	Changes in each component of accumulated other comprehensive items, net of tax are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2023 $ (2,941) $ (28) $ (255) $ (3,224) Other comprehensive income/(loss) before reclassifications 525 — (12) 513 Amounts reclassified from accumulated other comprehensive income/(loss) 7 3 4 14 Net other comprehensive income/(loss) 532 3 (8) 527 Balance at December 31, 2024 $ (2,409) $ (25) $ (263) $ (2,697)

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2024
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Disclosures	Supplemental cash flow information is as follows: (In millions) 2024 2023 2022 Cash paid for: Interest $ 1,570 $ 1,385 $ 667 Income taxes 1,834 1,482 1,234 Non-cash investing and financing activities Acquired but unpaid property, plant and equipment 303 296 393 Finance lease ROU assets obtained in exchange for new finance lease liabilities — 2 33 Declared but unpaid dividends 150 137 119 Issuance of stock upon vesting of restricted stock units 186 234 241 Excise tax from stock repurchases 26 28 —
Schedule of Cash, Cash Equivalents and Restricted Cash	Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows: December 31, December 31, (In millions) 2024 2023 Cash and cash equivalents $ 4,009 $ 8,077 Restricted cash included in other current assets 10 6 Restricted cash included in other assets 21 14 Cash, cash equivalents and restricted cash $ 4,040 $ 8,097

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Aggregate Notional Value of Outstanding Derivative Contracts	The following table provides the aggregate notional value of outstanding derivative contracts. December 31, December 31, (In millions) 2024 2023 Notional amount Cross-currency interest rate swaps designated as net investment hedge - euro $ 1,000 $ 1,000 Cross-currency interest rate swaps designated as net investment hedge - Japanese yen 4,650 4,650 Cross-currency interest rate swaps designated as net investment hedge - Swiss franc 2,500 2,500 Currency exchange contracts 1,588 1,567
Schedule of Fair Value of Derivative Instruments	While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income. Fair value – assets Fair value – liabilities December 31, December 31, December 31, December 31, (In millions) 2024 2023 2024 2023 Derivatives designated as hedging instruments Cross-currency interest rate swaps $ 458 $ 5 $ 57 $ 287 Derivatives not designated as hedging instruments Currency exchange contracts 2 3 2 3 Total derivatives $ 460 $ 8 $ 59 $ 290
Schedule of Derivative Instruments Gains and Losses	Gain/(loss) recognized (In millions) 2024 2023 2022 Fair value hedging relationships Cross-currency interest rate swaps Hedged long-term obligations - included in other income/(expense) $ — $ — $ 77 Derivatives designated as hedging instruments - included in other income/(expense) — — (81) Derivatives designated as cash flow hedges Interest rate swaps Amount reclassified from accumulated other comprehensive items to interest expense (3) (4) — Amount reclassified from accumulated other comprehensive items to other income/(loss) — (3) (3) Financial instruments designated as net investment hedges Foreign currency-denominated debt and other payables Included in currency translation adjustment within other comprehensive income/(loss) 686 (356) 695 Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive income/(loss) 682 (222) 52 Included in interest expense 267 120 19 Derivatives not designated as hedging instruments Currency exchange contracts Included in cost of product revenues 21 1 6 Included in other income/(expense) (16) (29) 102

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of Business Segment Information	Business Segment Information 2024 (In millions) Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Total Revenues Revenues from external customers $ 8,160 $ 7,267 $ 4,449 $ 23,002 $ 42,879 Intersegment revenues 1,471 196 63 155 1,885 9,631 7,463 4,512 23,157 44,764 Elimination of intersegment revenues (1,885) Consolidated revenues $ 42,879 Segment Income Cost of revenues 3,559 3,535 2,605 18,074 Selling, general, and administrative expenses 1,799 1,251 741 2,378 Research and development expenses 551 554 176 73 Other segment items 219 167 (168) (459) Segment income 3,503 1,955 1,159 3,090 9,707 Unallocated amounts Cost of revenues adjustments (47) Selling, general and administrative expenses adjustments 8 Restructuring and other costs (379) Amortization of acquisition-related intangible assets (1,952) Interest income 1,078 Interest expense (1,390) Other income/(expense) 12 Consolidated income before income taxes $ 7,037 (In millions) Unallocated amounts Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Consolidated Segment assets $ 84,031 $ 2,982 $ 2,944 $ 1,218 $ 6,145 $ 97,321 Purchases of property, plant and equipment 85 123 95 125 971 1,400 Depreciation of property, plant and equipment — 230 103 104 721 1,156 2023 (In millions) Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Total Revenues Revenues from external customers $ 8,545 $ 7,101 $ 4,324 $ 22,888 $ 42,857 Intersegment revenues 1,432 163 82 154 1,829 9,977 7,263 4,405 23,041 44,686 Elimination of intersegment revenues (1,829) Consolidated revenues $ 42,857 Segment Income Cost of revenues 4,072 3,468 2,592 18,033 Selling, general, and administrative expenses 1,791 1,252 724 2,304 Research and development expenses 558 528 156 68 Other segment items 136 107 (191) (722) Segment income 3,420 1,908 1,124 3,358 9,810 Unallocated amounts Cost of revenues adjustments (95) Selling, general and administrative expenses adjustments (59) Restructuring and other costs (459) Amortization of acquisition-related intangible assets (2,338) Interest income 879 Interest expense (1,375) Other income/(expense) (65) Consolidated income before income taxes $ 6,298 (In millions) Unallocated amounts Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Consolidated Segment assets $ 85,314 $ 3,186 $ 2,726 $ 1,150 $ 6,350 $ 98,726 Purchases of property, plant and equipment 80 178 87 121 1,013 1,479 Depreciation of property, plant and equipment — 220 93 86 669 1,068 2022 (In millions) Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Total Revenues Revenues from external customers $ 11,565 $ 6,441 $ 4,604 $ 22,304 $ 44,915 Intersegment revenues 1,967 182 158 207 2,515 13,532 6,624 4,763 22,511 47,430 Elimination of intersegment revenues (2,515) Consolidated revenues $ 44,915 Segment Income Cost of revenues 4,973 3,194 3,095 17,830 Selling, general, and administrative expenses 2,027 1,235 605 2,347 Research and development expenses 680 508 147 85 Other segment items 270 180 (108) (623) Segment income 5,582 1,507 1,024 2,872 10,985 Unallocated amounts Cost of revenues adjustments (46) Selling, general and administrative expenses adjustments (37) Restructuring and other costs (114) Amortization of acquisition-related intangible assets (2,395) Interest income 272 Interest expense (726) Other income/(expense) (104) Consolidated income before income taxes $ 7,835 (In millions) Unallocated amounts Life Sciences Solutions Analytical Instruments Specialty Diagnostics Laboratory Products and Biopharma Services Consolidated Segment assets $ 83,340 $ 3,845 $ 2,465 $ 1,076 $ 6,428 $ 97,154 Purchases of property, plant and equipment 98 490 140 112 1,403 2,243 Depreciation of property, plant and equipment — 214 83 75 614 986
Schedule of Revenue by Country Based on Customer Location	Geographical Information (In millions) 2024 2023 2022 Revenues United States $ 21,755 $ 22,013 $ 23,820 Other 21,124 20,844 21,095 Consolidated revenues $ 42,879 $ 42,857 $ 44,915 Long-lived Assets United States $ 6,245 $ 6,352 $ 6,308 Other 4,550 4,652 4,565 Consolidated long-lived assets $ 10,795 $ 11,004 $ 10,873

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Components of Purchase Price and Net Assets Acquired	The components of the purchase price and net assets acquired are as follows: (In millions) Olink Purchase price Cash paid $ 3,215 Purchase price payable 28 Cash acquired (97) $ 3,146 Net assets acquired Definite-lived intangible assets Customer relationships $ 708 Product technology 207 Tradenames 97 Goodwill 2,302 Net tangible assets 8 Deferred tax assets (liabilities) (176) $ 3,146 The components of the purchase price and net assets acquired are as follows: (In millions) The Binding Site CorEvitas Purchase price Cash paid $ 2,412 $ 730 Debt settled 307 184 Cash acquired (20) (4) $ 2,699 $ 910 Net assets acquired Definite-lived intangible assets Customer relationships $ 868 $ 260 Product technology 162 47 Tradenames 42 — Backlog — 46 Goodwill 1,741 627 Net tangible assets 174 (2) Deferred tax assets (liabilities) (288) (68) $ 2,699 $ 910

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Operating Leases	As a lessee, the consolidated financial statements include the following relating to operating leases: (Dollars in millions) 2024 2023 2022 Statement of income Operating lease costs $ 353 $ 355 $ 351 Variable lease costs 115 115 109 Statement of cash flows Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities $ 327 $ 410 $ 289 Operating lease ROU assets obtained in exchange for new operating lease liabilities 262 234 430 Balance sheet ROU assets - included in other assets $ 1,489 $ 1,556 Operating lease liabilities - included in other accrued expenses 261 263 Operating lease liabilities - included in other long-term liabilities 1,239 1,244 Weighted average at end of year Remaining operating lease term 8.6 years 9.2 years Discount rate 4.6 % 4.0 %
Schedule of Future Payments of Operating Lease Liabilities	As of December 31, 2024, future payments of operating lease liabilities are as follows: (In millions) 2025 $ 320 2026 277 2027 235 2028 167 2029 136 2030 and thereafter 723 Total lease payments 1,858 Less: imputed interest 357 Total operating lease liability $ 1,501

Pension and Other Postretirem_2

Pension and Other Postretirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Schedule of Reconciliation of Benefit Obligations and Plan Assets	The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans: Domestic pension benefits Non-U.S. pension benefits (In millions) 2024 2023 2024 2023 Accumulated benefit obligation $ 937 $ 1,005 $ 1,079 $ 1,166 Change in projected benefit obligations Projected benefit obligation at beginning of year $ 1,005 $ 995 $ 1,221 $ 1,069 Acquisitions — — — 15 Service costs — — 28 26 Interest costs 46 47 40 42 Settlements — — (29) (37) Plan participants' contributions — — 10 9 Actuarial (gains)/losses (32) 42 (59) 65 Benefits paid (81) (79) (26) (25) Currency translation and other — — (49) 57 Projected benefit obligation at end of year $ 937 $ 1,005 $ 1,135 $ 1,221 Change in fair value of plan assets Fair value of plan assets at beginning of year $ 947 $ 937 $ 944 $ 868 Acquisitions — — — 15 Actual return on plan assets 22 84 (37) 29 Employer contributions 7 5 37 36 Settlements — — (29) (37) Plan participants' contributions — — 10 9 Benefits paid (81) (79) (26) (25) Currency translation and other — — (32) 49 Fair value of plan assets at end of year $ 895 $ 947 $ 867 $ 944 Funded status $ (43) $ (58) $ (268) $ (277) Amounts recognized in balance sheet Noncurrent assets $ 5 $ — $ 57 $ 65 Current liability (5) (6) (12) (11) Noncurrent liabilities (42) (52) (313) (331) Net amount recognized $ (43) $ (58) $ (268) $ (277) Amounts recognized in accumulated other comprehensive items Net actuarial loss/(gain) $ 218 $ 217 $ 156 $ 151 Prior service (credits)/cost — — (7) (5) Net amount recognized $ 218 $ 217 $ 149 $ 146
Schedule of Actuarial Assumptions	The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2024 and 2023 and are as follows: Domestic pension benefits Non-U.S. pension benefits 2024 2023 2024 2023 Weighted average assumptions used to determine projected benefit obligations Discount rate for determining benefit obligation 5.48 % 4.82 % 3.74 % 3.47 % Interest crediting rate for cash balance plans 5.39 % 4.76 % 2.28 % 2.06 % Average rate of increase in employee compensation N/A N/A 2.58 % 2.64 % The actuarial assumptions used to compute the net periodic pension benefit cost/(income) are based upon information available as of the beginning of the year, as presented in the following table: Domestic pension benefits Non-U.S. pension benefits 2024 2023 2022 2024 2023 2022 Weighted average assumptions used to determine net benefit cost/(income) Discount rate - service cost N/A N/A N/A 3.00 % 3.62 % 1.00 % Discount rate - interest cost 4.82 % 5.01 % 2.70 % 3.48 % 3.95 % 1.36 % Interest crediting rate for cash balance plans 4.76 % 4.96 % 2.58 % 2.06 % 2.19 % 1.25 % Average rate of increase in employee compensation N/A N/A N/A 2.64 % 2.77 % 2.73 % Expected long-term rate of return on assets 6.00 % 6.25 % 4.75 % 4.28 % 4.33 % 2.33 %
Schedule of Projected Benefit Obligation and Fair Value of Plan Assets	The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in excess of plan assets are as follows: Pension plans (In millions) 2024 2023 Pension plans with projected benefit obligations in excess of plan assets Projected benefit obligation $ 727 $ 1,752 Fair value of plan assets 376 1,352
Schedule of Accumulated Benefit Obligation and Fair Value of Plan Assets	The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit obligations in excess of plan assets are as follows: Pension plans (In millions) 2024 2023 Pension plans with accumulated benefit obligations in excess of plan assets Accumulated benefit obligation $ 671 $ 1,695 Fair value of plan assets 376 1,349
Schedule of Net Benefit Costs	The net periodic pension benefit cost/(income) includes the following components: Domestic pension benefits Non-U.S. pension benefits (In millions) 2024 2023 2022 2024 2023 2022 Components of net benefit cost/(income) Service cost $ — $ — $ — $ 28 $ 26 $ 34 Interest cost on benefit obligation 46 47 27 40 42 20 Expected return on plan assets (56) (59) (45) (36) (37) (26) Amortization of actuarial net loss — — 4 4 2 7 Amortization of prior service cost/(benefit) — — — (1) (1) (1) Settlement/curtailment loss/(gain) — — — 2 1 (2) Net periodic benefit cost/(income) $ (10) $ (12) $ (14) $ 38 $ 33 $ 32
Schedule of Estimated Future Benefit Payments	Estimated future benefit payments during the next five years and in the aggregate for the five fiscal years thereafter, are as follows: (In millions) Domestic pension benefits Non-U.S. pension benefits Expected benefit payments 2025 $ 82 $ 54 2026 81 57 2027 81 58 2028 80 62 2029 79 66 2030-2034 373 405
Schedule of Fair Value of the Company's Plan Assets	The fair values of the company’s plan assets at December 31, 2024 and 2023, by asset category are as follows: December 31, Quoted Significant Significant Not subject to leveling (a) (In millions) 2024 (Level 1) (Level 2) (Level 3) Domestic pension plan assets U.S. equity funds $ 91 $ — $ — $ — $ 91 International equity funds 89 — — — 89 Fixed income funds 692 — — — 692 Money market funds 23 — — — 23 Total domestic pension plans $ 895 $ — $ — $ — $ 895 Non-U.S. pension plan assets Equity funds $ 7 $ — $ — $ — $ 7 Fixed income funds 288 7 — — 281 Multi-asset funds 69 — — — 69 Derivative funds 169 — — — 169 Insurance contracts 325 — 325 — — Cash / money market funds 9 4 — — 5 Total non-U.S. pension plans $ 867 $ 10 $ 325 $ — $ 532 (a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. December 31, Quoted Significant Significant Not subject to leveling (a) (In millions) 2023 (Level 1) (Level 2) (Level 3) Domestic pension plan assets U.S. equity funds $ 93 $ — $ — $ — $ 93 International equity funds 93 — — — 93 Fixed income funds 739 — — — 739 Money market funds 22 — — — 22 Total domestic pension plans $ 947 $ — $ — $ — $ 947 Non-U.S. pension plan assets Equity funds $ 7 $ — $ — $ — $ 7 Fixed income funds 346 9 — — 337 Multi-asset funds 66 — — — 66 Derivative funds 184 — — — 184 Alternative investments 1 — — — 1 Insurance contracts 333 — 333 — — Real estate funds 1 — — — 1 Cash / money market funds 6 4 — — 2 Total non-U.S. pension plans $ 944 $ 13 $ 333 $ — $ 598 (a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

Stock-based Compensation Expe_2

Stock-based Compensation Expense (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model	The weighted average assumptions used in the Black-Scholes option pricing model are as follows: 2024 2023 2022 Expected stock price volatility 25 % 25 % 26 % Risk free interest rate 4.3 % 4.2 % 2.0 % Expected life of options (years) 5.0 4.7 4.7 Expected annual dividend 0.3 % 0.3 % 0.2 % Weighted average per share grant-date fair values of options granted $ 166.92 $ 159.32 $ 135.07
Schedule of the Company's Option Activity	A summary of the company’s option activity for the year ended December 31, 2024 is presented below: Shares Weighted average exercise price Weighted average remaining contractual term Aggregate intrinsic Outstanding at December 31, 2023 5.0 $ 401.30 Granted 1.0 554.31 Exercised (1.2) 260.55 Canceled/expired (0.2) 559.45 Outstanding at December 31, 2024 4.5 $ 465.80 4.3 $ 358 Vested and unvested expected to vest at December 31, 2024 4.4 $ 462.90 4.2 $ 358 Exercisable at December 31, 2024 2.6 $ 403.06 2.9 $ 350
Schedule of the Company's Restricted Unit Activity	A summary of the company’s restricted unit activity for the year ended December 31, 2024 is presented below: Units Weighted Unvested at December 31, 2023 0.6 $ 533.65 Granted 0.4 556.83 Performance adjustments (0.1) 558.66 Vested (0.3) 524.55 Forfeited (0.1) 539.83 Unvested at December 31, 2024 0.6 $ 551.81

Nature of Operations and Summ_4

Nature of Operations and Summary of Significant Accounting Policies - Additional Accounting Policy and Balance Sheet Disclosures (Details) - PPD-SNBL K.K.	Dec. 31, 2024
Noncontrolling Interest [Line Items]
Ownership percentage, parent	60%
Ownership interest, noncontrolling owners	40%

Nature of Operations and Summ_5

Nature of Operations and Summary of Significant Accounting Policies - Stock-based Compensation Expense (Details)	12 Months Ended
	Dec. 31, 2024
Minimum | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Term	7 years
Minimum | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum | Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
Term	10 years
Maximum | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years

Nature of Operations and Summ_6

Nature of Operations and Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)	Dec. 31, 2024
Minimum | Buildings and improvements
Property, Plant and Equipment [Line Items]
Useful lives	25 years
Minimum | Machinery and Equipment
Property, Plant and Equipment [Line Items]
Useful lives	3 years
Maximum | Buildings and improvements
Property, Plant and Equipment [Line Items]
Useful lives	40 years
Maximum | Machinery and Equipment
Property, Plant and Equipment [Line Items]
Useful lives	10 years

Nature of Operations and Summ_7

Nature of Operations and Summary of Significant Accounting Policies - Acquisition-related Intangible Assets (Details)	Dec. 31, 2024
Maximum
Intangible Assets [Line Items]
Estimated useful life	20 years

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Components of Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 1,803	$ 2,057
Work in process	755	705
Finished goods	2,420	2,326
Inventories	$ 4,978	$ 5,088

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Schedule of Contract Asset and Liability Balances (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract assets, net	$ 1,435	$ 1,443
Noncurrent contract assets, net	6	4
Current contract liabilities	2,852	2,689
Noncurrent contract liabilities	$ 1,138	$ 1,499

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Remaining performance obligation amount	$ 24,610
Other intangible assets	34	$ 37
Equity method investments	357	489
Fair value of investments	0	5
Cost method investments	41	12
Investments measured at NAV	$ 40	$ 28
Minimum
Disaggregation of Revenue [Line Items]
Warranty agreement (in years)	3 years
Maximum
Disaggregation of Revenue [Line Items]
Warranty agreement (in years)	5 years
Estimated useful life	20 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Disaggregation of Revenue [Line Items]
Remaining performance obligation percentage	53%
Remaining performance obligation, expected timing	12 months

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 16,059	$ 15,524
Less: Accumulated depreciation and amortization	6,753	6,076
Property, plant and equipment, net	9,306	9,448
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	439	458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	3,728	3,593
Machinery, equipment and leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	9,858	9,235
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 2,034	$ 2,238

Supplemental Balance Sheet In_7

Supplemental Balance Sheet Information - Acquisition-related Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Definite-lived intangible assets, gross	$ 30,991	$ 31,374
Accumulated Amortization	(16,693)	(15,939)
Estimated future amortization expense of definite-lived intangible assets	14,298	15,435
Acquisition-related intangible assets	32,226	32,609
Acquisition-related intangible assets, net	15,533	16,670
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
2025	1,665
2026	1,496
2027	1,467
2028	1,436
2029	1,324
2030 and thereafter	6,911
Estimated future amortization expense of definite-lived intangible assets	14,298	15,435
Tradenames
Intangible Assets [Line Items]
Indefinite-lived intangible assets	1,235	1,235
Customer relationships
Intangible Assets [Line Items]
Definite-lived intangible assets, gross	22,644	22,762
Accumulated Amortization	(10,047)	(9,410)
Estimated future amortization expense of definite-lived intangible assets	12,596	13,352
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
Estimated future amortization expense of definite-lived intangible assets	12,596	13,352
Product technology
Intangible Assets [Line Items]
Definite-lived intangible assets, gross	5,557	5,894
Accumulated Amortization	(4,423)	(4,591)
Estimated future amortization expense of definite-lived intangible assets	1,134	1,303
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
Estimated future amortization expense of definite-lived intangible assets	1,134	1,303
Tradenames
Intangible Assets [Line Items]
Definite-lived intangible assets, gross	1,706	1,634
Accumulated Amortization	(1,180)	(1,079)
Estimated future amortization expense of definite-lived intangible assets	527	555
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
Estimated future amortization expense of definite-lived intangible assets	527	555
Backlog
Intangible Assets [Line Items]
Definite-lived intangible assets, gross	1,084	1,084
Accumulated Amortization	(1,043)	(859)
Estimated future amortization expense of definite-lived intangible assets	41	225
Finite-Lived Intangible Assets, Net, Future Amortization Expense [Abstract]
Estimated future amortization expense of definite-lived intangible assets	$ 41	$ 225

Supplemental Balance Sheet In_8

Supplemental Balance Sheet Information - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Beginning balance	$ 44,020	$ 41,196
Acquisitions	2,302	2,399
Currency translation	(470)	425
Ending balance	45,853	44,020
Life Sciences Solutions
Goodwill [Roll Forward]
Beginning balance	10,151	10,146
Acquisitions	2,302	0
Currency translation	(117)	5
Ending balance	12,336	10,151
Analytical Instruments
Goodwill [Roll Forward]
Beginning balance	5,051	4,965
Acquisitions	0	31
Currency translation	(92)	55
Ending balance	4,959	5,051
Specialty Diagnostics
Goodwill [Roll Forward]
Beginning balance	4,923	3,091
Acquisitions	0	1,741
Currency translation	(139)	91
Ending balance	4,784	4,923
Laboratory Products and Biopharma Services
Goodwill [Roll Forward]
Beginning balance	23,895	22,994
Acquisitions	0	627
Currency translation	(122)	274
Ending balance	$ 23,773	$ 23,895

Debt and Other Financing Arra_3

Debt and Other Financing Arrangements - Schedule of Debt (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total borrowings at par value	$ 31,332	$ 35,028
Unamortized discount	(95)	(113)
Unamortized debt issuance costs	(164)	(188)
Total borrowings at carrying value	31,072	34,727
Finance lease liabilities	202	190
Less: Short-term obligations and current maturities	2,214	3,609
Long-term obligations	$ 29,061	$ 31,308
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Long-term obligations	Long-term obligations
Senior notes
Debt Instrument [Line Items]
Total borrowings at carrying value	$ 30,999	$ 34,650
Senior notes | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.75%
Term	8 years
Total borrowings at par value	$ 0	1,104
Senior notes | 1.215% 3-Year Senior Notes, Due 10/18/2024
Debt Instrument [Line Items]
Interest rate	1.215%
Term	3 years
Total borrowings at par value	$ 0	2,500
Senior notes | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.125%
Term	5 years 6 months
Effective interest rate	0.40%
Total borrowings at par value	$ 828	883
Senior notes | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2%
Term	10 years
Effective interest rate	2.07%
Total borrowings at par value	$ 663	706
Senior notes | 0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	0.853%
Term	3 years
Effective interest rate	1.05%
Total borrowings at par value	$ 142	158
Senior notes | 0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0%
Term	4 years
Effective interest rate	0.14%
Total borrowings at par value	$ 569	607
Senior notes | 3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	3.20%
Term	3 years
Effective interest rate	3.38%
Total borrowings at par value	$ 518	552
Senior notes | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.40%
Term	8 years 6 months
Effective interest rate	1.52%
Total borrowings at par value	$ 725	773
Senior notes | 4.953% 3-Year Senior Notes, Due 8/10/2026
Debt Instrument [Line Items]
Interest rate	4.953%
Term	3 years
Effective interest rate	5.18%
Total borrowings at par value	$ 600	600
Senior notes | 5.000% 3-Year Senior Notes, Due 12/5/2026
Debt Instrument [Line Items]
Interest rate	5%
Term	3 years
Effective interest rate	5.26%
Total borrowings at par value	$ 1,000	1,000
Senior notes | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.45%
Term	10 years
Effective interest rate	1.64%
Total borrowings at par value	$ 518	552
Senior notes | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.75%
Term	7 years
Effective interest rate	1.96%
Total borrowings at par value	$ 621	662
Senior notes | 1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.054%
Term	5 years
Effective interest rate	1.18%
Total borrowings at par value	$ 184	205
Senior notes | 4.80% 5-Year Senior Notes, Due 11/21/2027
Debt Instrument [Line Items]
Interest rate	4.80%
Term	5 years
Effective interest rate	5%
Total borrowings at par value	$ 600	600
Senior notes | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.50%
Term	8 years 6 months
Effective interest rate	0.76%
Total borrowings at par value	$ 828	883
Senior notes | 1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.6525%
Term	4 years
Effective interest rate	1.79%
Total borrowings at par value	$ 364	0
Senior notes | 0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	0.77%
Term	5 years
Effective interest rate	0.90%
Total borrowings at par value	$ 184	206
Senior notes | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.375%
Term	12 years
Effective interest rate	1.46%
Total borrowings at par value	$ 621	662
Senior notes | 1.750% 7-Year Senior Notes, Due 10/15/2028
Debt Instrument [Line Items]
Interest rate	1.75%
Term	7 years
Effective interest rate	1.89%
Total borrowings at par value	$ 700	700
Senior notes | 5.000% 5-Year Senior Notes Due 1/31/2029
Debt Instrument [Line Items]
Interest rate	5%
Term	5 years
Effective interest rate	5.24%
Total borrowings at par value	$ 1,000	1,000
Senior notes | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.95%
Term	12 years
Effective interest rate	2.07%
Total borrowings at par value	$ 725	773
Senior notes | 2.60% 10-Year Senior Notes, Due 10/1/2029
Debt Instrument [Line Items]
Interest rate	2.60%
Term	10 years
Effective interest rate	2.74%
Total borrowings at par value	$ 900	900
Senior notes | 1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.279%
Term	7 years
Effective interest rate	1.44%
Total borrowings at par value	$ 30	33
Senior notes | 4.977% 7-Year Senior Notes, Due 8/10/2030
Debt Instrument [Line Items]
Interest rate	4.977%
Term	7 years
Effective interest rate	5.12%
Total borrowings at par value	$ 750	750
Senior notes | 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.80%
Term	9 years
Effective interest rate	0.88%
Total borrowings at par value	$ 1,812	1,932
Senior notes | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	0.875%
Term	12 years
Effective interest rate	1.13%
Total borrowings at par value	$ 932	993
Senior notes | 2.00% 10-Year Senior Notes, Due 10/15/2031
Debt Instrument [Line Items]
Interest rate	2%
Term	10 years
Effective interest rate	2.23%
Total borrowings at par value	$ 1,200	1,200
Senior notes | 1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.8401%
Term	8 years
Effective interest rate	1.92%
Total borrowings at par value	$ 457	0
Senior notes | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2.375%
Term	12 years
Effective interest rate	2.54%
Total borrowings at par value	$ 621	662
Senior notes | 1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.49%
Term	10 years
Effective interest rate	1.60%
Total borrowings at par value	$ 40	45
Senior notes | 4.95% 10-Year Senior Notes, Due 11/21/2032
Debt Instrument [Line Items]
Interest rate	4.95%
Term	10 years
Effective interest rate	5.09%
Total borrowings at par value	$ 600	600
Senior notes | 5.086% 10-Year Senior Notes, Due 8/10/2033
Debt Instrument [Line Items]
Interest rate	5.086%
Term	10 years
Effective interest rate	5.20%
Total borrowings at par value	$ 1,000	1,000
Senior notes | 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.125%
Term	12 years
Effective interest rate	1.20%
Total borrowings at par value	$ 1,553	1,656
Senior notes | 5.200% 10-Year Senior Notes, Due 1/31/2034
Debt Instrument [Line Items]
Interest rate	5.20%
Term	10 years
Effective interest rate	5.34%
Total borrowings at par value	$ 500	500
Senior notes | 3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	3.65%
Term	12 years
Effective interest rate	3.76%
Total borrowings at par value	$ 777	828
Senior notes | 1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	1.50%
Term	12 years
Effective interest rate	1.58%
Total borrowings at par value	$ 137	152
Senior notes | 2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	2.0375%
Term	12 years
Effective interest rate	2.10%
Total borrowings at par value	$ 358	0
Senior notes | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2.875%
Term	20 years
Effective interest rate	2.94%
Total borrowings at par value	$ 725	773
Senior notes | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.50%
Term	20 years
Effective interest rate	1.73%
Total borrowings at par value	$ 932	993
Senior notes | 2.80% 20-Year Senior Notes, Due 10/15/2041
Debt Instrument [Line Items]
Interest rate	2.80%
Term	20 years
Effective interest rate	2.90%
Total borrowings at par value	$ 1,200	1,200
Senior notes | 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.625%
Term	20 years
Effective interest rate	1.76%
Total borrowings at par value	$ 1,294	1,380
Senior notes | 2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	2.069%
Term	20 years
Effective interest rate	2.13%
Total borrowings at par value	$ 93	104
Senior notes | 5.404% 20-Year Senior Notes, Due 8/10/2043
Debt Instrument [Line Items]
Interest rate	5.404%
Term	20 years
Effective interest rate	5.50%
Total borrowings at par value	$ 600	600
Senior notes | 2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	2.02%
Term	20 years
Effective interest rate	2.06%
Total borrowings at par value	$ 184	206
Senior notes | 5.30% 30-Year Senior Notes, Due 2/1/2044
Debt Instrument [Line Items]
Interest rate	5.30%
Term	30 years
Effective interest rate	5.37%
Total borrowings at par value	$ 400	400
Senior notes | 4.10% 30-Year Senior Notes, Due 8/15/2047
Debt Instrument [Line Items]
Interest rate	4.10%
Term	30 years
Effective interest rate	4.23%
Total borrowings at par value	$ 750	750
Senior notes | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	1.875%
Term	30 years
Effective interest rate	1.98%
Total borrowings at par value	$ 1,035	1,104
Senior notes | 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
Debt Instrument [Line Items]
Interest rate	2%
Term	30 years
Effective interest rate	2.06%
Total borrowings at par value	$ 777	828
Senior notes | 2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated)
Debt Instrument [Line Items]
Interest rate	2.382%
Term	30 years
Effective interest rate	2.43%
Total borrowings at par value	$ 212	236
Other
Debt Instrument [Line Items]
Total borrowings at par value	73	77
Total borrowings at carrying value	$ 73	$ 77

Debt and Other Financing Arra_4

Debt and Other Financing Arrangements - Schedule of Annual Repayment Requirements for Debt Obligations (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Borrowings
2025	$ 2,202
2026	2,843
2027	1,923
2028	2,726
2029	2,655
2030 and thereafter	18,983
Total borrowings at par value	31,332	$ 35,028
Finance Lease Liabilities
2025	12
2026	12
2027	10
2028	9
2029	8
2030 and thereafter	151
Finance lease liabilities	$ 202	$ 190

Debt and Other Financing Arra_5

Debt and Other Financing Arrangements - Narrative (Details)	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2022 USD ($)
Short-term Financing [Line Items]
Unused lines of credit	$ 65,000,000
Loss on early extinguishment of debt		$ (26,000,000)
Senior notes
Short-term Financing [Line Items]
Redemption price	100%
U.S. Commercial Paper Program | Commercial paper
Short-term Financing [Line Items]
Maximum period prior to maturity	397 days
Euro Commercial Paper Program | Commercial paper
Short-term Financing [Line Items]
Maximum period prior to maturity	183 days
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) | Senior notes
Short-term Financing [Line Items]
Interest rate	0%
Senior Notes 3.650% Due 2025 | Senior notes
Short-term Financing [Line Items]
Interest rate		3.65%
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) | Senior notes
Short-term Financing [Line Items]
Interest rate	0.80%
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) | Senior notes
Short-term Financing [Line Items]
Interest rate	1.125%
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) | Senior notes
Short-term Financing [Line Items]
Interest rate	1.625%
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) | Senior notes
Short-term Financing [Line Items]
Interest rate	2%
Revolving Credit Facility
Short-term Financing [Line Items]
Revolving credit facility capacity	$ 5,000,000,000
Minimum consolidated net interest coverage ratio	3.5
Borrowings outstanding	$ 0

Debt and Other Financing Arra_6

Debt and Other Financing Arrangements - Schedule of Subsequent Events (Details) - Senior notes - Subsequent Event SFr in Millions	3 Months Ended
	Mar. 31, 2025 CHF (SFr)
0.790% 3-Year Senior Notes, Due January 6, 2028 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	0.79%
Term	3 years
Principal Value Issued	SFr 88
1.120% 5-Year Senior Notes, Due January 6, 2030 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.12%
Term	5 years
Principal Value Issued	SFr 234
1.520% 12-Year Senior Notes, Due January 6, 2037 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.52%
Term	12 years
Principal Value Issued	SFr 311
1.490% 20-Year Senior Notes, Due January 6, 2045 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.49%
Term	20 years
Principal Value Issued	SFr 185
1.470% 25-Year Senior Notes, Due January 6, 2050 (Swiss franc-denominated)
Debt Instrument [Line Items]
Interest rate	1.47%
Term	25 years
Principal Value Issued	SFr 327

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Assets
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other assets
Liabilities
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities
Fair Value, Recurring
Assets
Cash equivalents	$ 1,103	$ 5,021
Bank time deposits	1,560	3
Investments	39	20
Insurance contracts	240	210
Derivative contracts	460	8
Total assets	3,401	5,262
Liabilities
Derivative contracts	59	290
Contingent consideration	13	87
Total liabilities	72	377
Fair Value, Recurring | Quoted Prices in Active Markets (Level 1)
Assets
Cash equivalents	1,103	5,021
Bank time deposits	1,560	3
Investments	18	20
Insurance contracts	0	0
Derivative contracts	0	0
Total assets	2,680	5,044
Liabilities
Derivative contracts	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)
Assets
Cash equivalents	0	0
Bank time deposits	0	0
Investments	0	0
Insurance contracts	240	210
Derivative contracts	460	8
Total assets	700	218
Liabilities
Derivative contracts	59	290
Contingent consideration	0	0
Total liabilities	59	290
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)
Assets
Cash equivalents	0	0
Bank time deposits	0	0
Investments	21	0
Insurance contracts	0	0
Derivative contracts	0	0
Total assets	21	0
Liabilities
Derivative contracts	0	0
Contingent consideration	13	87
Total liabilities	$ 13	$ 87

Fair Value Measurements - Liabi

Fair Value Measurements - Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Investments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 0
Purchases	21
Ending balance	21	$ 0
Contingent consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	87	174
Acquisitions (including assumed balances)	0	1
Payments	(2)	(63)
Changes in fair value included in earnings	(73)	(25)
Ending balance	$ 13	$ 87
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible Enumeration]	Selling, general and administrative expenses	Selling, general and administrative expenses

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value	$ 31,072	$ 34,727
Fair value	28,527	32,268
Senior notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value	30,999	34,650
Fair value	28,454	32,191
Other
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value	73	77
Fair value	$ 73	$ 77

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Dec. 31, 2024 USD ($)
Loss Contingencies [Line Items]
Unconditional purchase obligations	$ 2,200
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration]	Other accrued expenses, Other long-term liabilities
Environmental liability	$ 81
Product Liability, Workers Compensation and Other Personal Injury Matters
Loss Contingencies [Line Items]
Loss accrual	225
Estimated amounts due from insurers	83
Undiscounted product liability accrual	21
Minimum | Product Liability, Workers Compensation and Other Personal Injury Matters
Loss Contingencies [Line Items]
Range of probable loss	224
Maximum | Product Liability, Workers Compensation and Other Personal Injury Matters
Loss Contingencies [Line Items]
Range of probable loss	381
Letters of Credit / Bank Guarantees
Loss Contingencies [Line Items]
Maximum guarantee under lease arrangements	335
Surety Bonds and Other Guarantees
Loss Contingencies [Line Items]
Maximum guarantee under lease arrangements	123
Investments
Loss Contingencies [Line Items]
Maximum guarantee under lease arrangements	182
Pension Obligation Guarantee | Businesses Sold
Loss Contingencies [Line Items]
Maximum guarantee under lease arrangements	$ 25

Supplemental Income Statement_3

Supplemental Income Statement Information - Scheduleof Disaggregated Revenues (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Consolidated revenues	$ 42,879	$ 42,857	$ 44,915
North America
Disaggregation of Revenue [Line Items]
Consolidated revenues	22,504	22,764	24,594
Europe
Disaggregation of Revenue [Line Items]
Consolidated revenues	10,857	10,741	10,762
Asia-Pacific
Disaggregation of Revenue [Line Items]
Consolidated revenues	7,956	7,873	8,115
Other regions
Disaggregation of Revenue [Line Items]
Consolidated revenues	1,561	1,479	1,444
Consumables
Disaggregation of Revenue [Line Items]
Consolidated revenues	17,587	17,597	20,624
Instruments
Disaggregation of Revenue [Line Items]
Consolidated revenues	7,446	7,646	7,924
Services
Disaggregation of Revenue [Line Items]
Consolidated revenues	$ 17,845	$ 17,614	$ 16,367

Supplemental Income Statement_4

Supplemental Income Statement Information - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Feb. 20, 2025
Restructuring Cost and Reserve [Line Items]
Workforce reduction	2%	5%	2%
Gain (loss) on investments	$ 21	$ (46)	$ (161)
Net gains on derivative instruments			67
Gain (Loss) on extinguishment of debt			(26)
Foreign currency transaction gains (losses)	$ 0	$ (67)	$ 62
Subsequent Event
Restructuring Cost and Reserve [Line Items]
Future restructuring costs				$ 200

Supplemental Income Statement_5

Supplemental Income Statement Information - Schedule of Restructuring and Other Costs by Segment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	$ 379	$ 459	$ 114
Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	9	15	3
Life Sciences Solutions | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	69	105	30
Analytical Instruments | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	4	33	1
Specialty Diagnostics | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	17	11	68
Laboratory Products and Biopharma Services | Total Reportable Segments
Restructuring Cost and Reserve [Line Items]
Restructuring and other costs	$ 280	$ 295	$ 12

Supplemental Income Statement_6

Supplemental Income Statement Information - Schedule of Changes in the Company's Accrued Restructuring Balance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Reserve [Roll Forward]
Beginning balance	$ 60	$ 41	$ 17
Net restructuring charges incurred	97	194	68
Payments	(105)	(175)	(44)
Currency translation	(2)
Ending balance	$ 50	$ 60	41
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Restructuring and other costs	Restructuring and other costs
Non-cash charges	$ 282	$ 264	$ 46
Impairment of long-lived assets	211	126
Loss on contract termination		26
Pre-acquisition litigation costs		19
Impairment of disposal group	41	93
Loss attributable to noncontrolling interest	$ 19	$ 46
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]	Restructuring and other costs

Supplemental Income Statement_7

Supplemental Income Statement Information - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Net income attributable to Thermo Fisher Scientific Inc.	$ 6,335	$ 5,995	$ 6,950
Basic weighted average shares (in shares)	382	386	392
Plus effect of: stock options and restricted stock units (in shares)	1	2	2
Diluted weighted average shares (in shares)	383	388	394
Basic earnings per share (in dollars per share)	$ 16.58	$ 15.52	$ 17.75
Diluted earnings per share (in dollars per share)	$ 16.53	$ 15.45	$ 17.63
Antidilutive stock options excluded from diluted weighted averages shares (shares)	2	2	2

Income Taxes - Components of In

Income Taxes - Components of Income Before Provision for Income Taxes and Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Components of Income From Continuing Operations Before Income Taxes [Abstract]
U.S.	$ 2,226	$ 2,431	$ 3,859
Non-U.S.	4,812	3,867	3,976
Income before income taxes	7,037	6,298	7,835
Current income tax provision
Federal	561	228	813
Non-U.S.	1,175	1,206	633
State	130	150	254
Current income tax provision	1,866	1,584	1,700
Deferred income tax provision/(benefit)
Federal	(1,026)	(551)	(611)
Non-U.S.	(72)	(647)	(314)
State	(111)	(102)	(72)
Deferred income tax provision (benefit)	(1,209)	(1,300)	(997)
Provision for/(benefit from) income taxes	$ 657	$ 284	$ 703

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	21%	21%	21%
Provision for income taxes at statutory rate	$ 1,478	$ 1,323	$ 1,645
Foreign rate differential	(131)	(223)	(329)
Income tax credits	(333)	(276)	(202)
Global intangible low-taxed income	57	113	96
Foreign-derived intangible income	(133)	(108)	(149)
Excess tax benefits from stock options and restricted stock units	(67)	(69)	(80)
Provision for (reversal of) tax reserves, net	218	13	(544)
Intra-entity transfers	(106)	(233)	(18)
Foreign exchange loss on inter-company debt refinancing	0	(112)	0
Provision for (reversal of) valuation allowances, net	(229)	(32)	344
Withholding taxes	74	33	84
Tax return reassessments and settlements	(192)	(187)	(210)
State income taxes, net of federal tax	66	70	111
Other, net	(45)	(28)	(45)
Provision for/(benefit from) income taxes	$ 657	$ 284	$ 703

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) country	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Operating Loss Carryforwards [Line Items]
Countries with taxable presence | country	70
Provision for (reversal of) valuation allowances, net	$ (229)	$ (32)	$ 344
Research credits and incentives		127
Tax benefit from foreign exchange loss on an intercompany debt refinancing transaction		91
Intra-entity transfers	(106)	(233)	(18)
Tax return reassessments and settlements	192	187	210
Excess tax benefits from stock options and restricted stock units	(67)	(69)	(80)
Undistributed earnings	40,000
Unrecognized tax benefits	525	540	572	$ 1,124
Additions due to acquisitions	19	0	15
UTB, interest and penalties	75	95
Foreign Tax Credit Carryforwards
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	729
Deferred Interest Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	534
Deferred Interest Carryforward | Tax Years 2025-2034
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	201
Non- U.S.
Operating Loss Carryforwards [Line Items]
Provision for (reversal of) tax reserves, net	240
Provision for (reversal of) valuation allowances, net	(459)
NOL carryforwards	1,540
Federal
Operating Loss Carryforwards [Line Items]
NOL carryforwards	109
State
Operating Loss Carryforwards [Line Items]
NOL carryforwards	63
Domestic NOL Expires
Operating Loss Carryforwards [Line Items]
NOL carryforwards	43
State NOL Expires
Operating Loss Carryforwards [Line Items]
NOL carryforwards	54
Portion of Non- U.S. with expiration dates
Operating Loss Carryforwards [Line Items]
NOL carryforwards	574
Federal
Operating Loss Carryforwards [Line Items]
Provision for (reversal of) tax reserves, net			(658)
Provision for (reversal of) valuation allowances, net			395
Tax return reassessments and settlements			208
Charge for expired tax credits			49
Unrecognized tax benefits reclassed to accrued income taxes in connection with IRS settlement			101
Foreign
Operating Loss Carryforwards [Line Items]
Increase (decrease) in UTB	(99)	(12)	143
Federal and State
Operating Loss Carryforwards [Line Items]
Increase (decrease) in UTB	$ (84)	$ (19)	$ (610)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Asset (Liability) and Changes in Valuation Allowance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets (Liabilities) [Abstract]
Depreciation and amortization	$ (4,133)	$ (4,286)
Net operating loss and credit carryforwards	2,915	2,385
Reserves and accruals	161	157
Accrued compensation	318	299
Inventory basis difference	309	275
Deferred interest	534	753
Research and development and other capitalized costs	536	380
Unrealized (gains) losses on hedging instruments	(363)	(66)
Contract liabilities	280	130
Other, net	147	199
Deferred tax assets/(liabilities), net before valuation allowance	705	226
Less: Valuation allowance	1,043	1,317	$ 1,322
Deferred tax assets/(liabilities), net	(338)	(1,091)
Valuation Allowance [Roll Forward]
Beginning Balance	1,317	1,322	968
Additions/(reductions) recognized in income tax provision, net	(229)	(32)	344
Additions due to acquisitions	0	4	14
Currency translation and other	(46)	23	(4)
Ending Balance	$ 1,043	$ 1,317	$ 1,322

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Beginning balance	$ 540	$ 572	$ 1,124
Additions due to acquisitions	19	0	15
Additions for tax positions of current year	91	4	104
Additions for tax positions of prior years	244	34	24
Reductions for tax positions of prior years	(182)	(43)	(659)
Closure of tax years	0	(6)	(4)
Settlements	(187)	(21)	(32)
Ending balance	$ 525	$ 540	$ 572

Comprehensive Income_(Loss) a_3

Comprehensive Income/(Loss) and Shareholders' Equity - Schedule of Changes in Each Component of Accumulated Other Comprehensive Items (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 46,724	$ 44,032	$ 40,855
Total other comprehensive income/(loss)	520	(133)	(777)
Ending Balance	49,551	46,724	44,032
Currency translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(2,941)
Other comprehensive income/(loss) before reclassifications	525
Amounts reclassified from accumulated other comprehensive income/(loss)	7
Total other comprehensive income/(loss)	532
Ending Balance	(2,409)	(2,941)
Unrealized gains/(losses) on hedging instruments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(28)
Other comprehensive income/(loss) before reclassifications	0
Amounts reclassified from accumulated other comprehensive income/(loss)	3
Total other comprehensive income/(loss)	3
Ending Balance	(25)	(28)
Pension and other postretirement benefit liability adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(255)
Other comprehensive income/(loss) before reclassifications	(12)
Amounts reclassified from accumulated other comprehensive income/(loss)	4
Total other comprehensive income/(loss)	(8)
Ending Balance	(263)	(255)
Total
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(3,224)	(3,099)	(2,329)
Other comprehensive income/(loss) before reclassifications	513
Amounts reclassified from accumulated other comprehensive income/(loss)	14
Total other comprehensive income/(loss)	527
Ending Balance	$ (2,697)	$ (3,224)	$ (3,099)

Comprehensive Income_(Loss) a_4

Comprehensive Income/(Loss) and Shareholders' Equity - Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unissued shares of common stock (in shares)		37
Purchases of company common stock		$ 4,000	$ 3,000	$ 3,000
Subsequent Event
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchases of company common stock	$ 2,000
Purchases of company common stock (in shares)	3.6

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Disclosures (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Supplemental Cash Flow Information [Abstract]
Interest	$ 1,570	$ 1,385	$ 667
Income taxes	1,834	1,482	1,234
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment	303	296	393
Finance lease ROU assets obtained in exchange for new finance lease liabilities	0	2	33
Declared but unpaid dividends	150	137	119
Issuance of stock upon vesting of restricted stock units	186	234	241
Excise tax from stock repurchases	$ 26	$ 28	$ 0

Supplemental Cash Flow Inform_4

Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Supplemental Cash Flow Information [Abstract]
Cash and cash equivalents	$ 4,009	$ 8,077
Restricted cash included in other current assets	10	6
Restricted cash included in other assets	21	14
Cash, cash equivalents and restricted cash	$ 4,040	$ 8,097	$ 8,537	$ 4,491
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets	Other current assets
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets

Derivatives - Derivative Assets

Derivatives - Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Recurring
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 460	$ 8
Derivative Liability	59	290
Interest Rate Swap | Financial instruments designated as net investment hedges | Cross-currency interest rate swaps designated as net investment hedge - euro
Derivatives, Fair Value [Line Items]
Notional amount	1,000	1,000
Interest Rate Swap | Financial instruments designated as net investment hedges | Cross-currency interest rate swaps designated as net investment hedge - Japanese yen
Derivatives, Fair Value [Line Items]
Notional amount	4,650	4,650
Interest Rate Swap | Financial instruments designated as net investment hedges | Cross-currency interest rate swaps designated as net investment hedge - Swiss franc
Derivatives, Fair Value [Line Items]
Notional amount	2,500	2,500
Currency exchange contracts
Derivatives, Fair Value [Line Items]
Notional amount	1,588	1,567
Currency exchange contracts | Derivatives not designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Asset	2	3
Derivative Liability	2	3
Cross-currency interest rate swaps | Derivatives designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Asset	458	5
Derivative Liability	$ 57	$ 287

Derivatives - Derivative Instru

Derivatives - Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Currency exchange contracts | Other Expense | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative	$ (16)	$ (29)	$ 102
Currency exchange contracts | Included in cost of product revenues | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative	21	1	6
Fair value hedging relationships | Cross-currency interest rate swaps | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative	0	0	(81)
Fair value hedging relationships | Cross-currency interest rate swaps | Other Expense | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Hedged long-term obligations - included in other income/(expense)	0	0	77
Derivatives designated as cash flow hedges | Interest Rate Swap | Other Expense | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount reclassified from accumulated other comprehensive items to interest expense	0	(3)	(3)
Derivatives designated as cash flow hedges | Interest Rate Swap | Amount reclassified from accumulated other comprehensive items to interest expense | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount reclassified from accumulated other comprehensive items to interest expense	(3)	(4)	0
Financial instruments designated as net investment hedges | Cross-currency interest rate swaps | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative	267	120	19
Included in currency translation adjustment within other comprehensive income/(loss)	682	(222)	52
Financial instruments designated as net investment hedges | Foreign currency-denominated debt and other payables | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Included in currency translation adjustment within other comprehensive income/(loss)	$ 686	$ (356)	$ 695

Business Segment and Geograph_3

Business Segment and Geographical Information - Narrative (Details)	12 Months Ended
	Dec. 31, 2024 Segment
Segment Reporting [Abstract]
Reportable segments	4

Business Segment and Geograph_4

Business Segment and Geographical Information - Schedule of Business Segment Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Consolidated revenues	$ 42,879	$ 42,857	$ 44,915
Selling, general and administrative expenses	8,595	8,445	8,993
Research and development expenses	1,390	1,337	1,471
Segment income	7,337	6,859	8,393
Restructuring and other costs	(379)	(459)	(114)
Amortization of acquisition-related intangible assets	(1,952)	(2,338)	(2,395)
Interest income	1,078	879	272
Interest expense	(1,390)	(1,375)	(726)
Other income/(expense)	12	(65)	(104)
Income before income taxes	7,037	6,298	7,835
Segment assets	97,321	98,726	97,154
Purchases of property, plant and equipment	1,400	1,479	2,243
Depreciation of property, plant and equipment	1,156	1,068	986
Life Sciences Solutions
Segment Reporting Information [Line Items]
Consolidated revenues	8,160	8,545	11,565
Analytical Instruments
Segment Reporting Information [Line Items]
Consolidated revenues	7,267	7,101	6,441
Specialty Diagnostics
Segment Reporting Information [Line Items]
Consolidated revenues	4,449	4,324	4,604
Laboratory Products and Biopharma Services
Segment Reporting Information [Line Items]
Consolidated revenues	23,002	22,888	22,304
Elimination of intersegment revenues
Segment Reporting Information [Line Items]
Consolidated revenues	1,885	1,829	2,515
Elimination of intersegment revenues | Life Sciences Solutions
Segment Reporting Information [Line Items]
Consolidated revenues	1,471	1,432	1,967
Elimination of intersegment revenues | Analytical Instruments
Segment Reporting Information [Line Items]
Consolidated revenues	196	163	182
Elimination of intersegment revenues | Specialty Diagnostics
Segment Reporting Information [Line Items]
Consolidated revenues	63	82	158
Elimination of intersegment revenues | Laboratory Products and Biopharma Services
Segment Reporting Information [Line Items]
Consolidated revenues	155	154	207
Operating Segments
Segment Reporting Information [Line Items]
Consolidated revenues	44,764	44,686	47,430
Segment income	9,707	9,810	10,985
Operating Segments | Life Sciences Solutions
Segment Reporting Information [Line Items]
Consolidated revenues	9,631	9,977	13,532
Cost of revenues	3,559	4,072	4,973
Selling, general and administrative expenses	1,799	1,791	2,027
Research and development expenses	551	558	680
Other segment items	219	136	270
Segment income	3,503	3,420	5,582
Restructuring and other costs	(69)	(105)	(30)
Segment assets	2,982	3,186	3,845
Purchases of property, plant and equipment	123	178	490
Depreciation of property, plant and equipment	230	220	214
Operating Segments | Analytical Instruments
Segment Reporting Information [Line Items]
Consolidated revenues	7,463	7,263	6,624
Cost of revenues	3,535	3,468	3,194
Selling, general and administrative expenses	1,251	1,252	1,235
Research and development expenses	554	528	508
Other segment items	167	107	180
Segment income	1,955	1,908	1,507
Restructuring and other costs	(4)	(33)	(1)
Segment assets	2,944	2,726	2,465
Purchases of property, plant and equipment	95	87	140
Depreciation of property, plant and equipment	103	93	83
Operating Segments | Specialty Diagnostics
Segment Reporting Information [Line Items]
Consolidated revenues	4,512	4,405	4,763
Cost of revenues	2,605	2,592	3,095
Selling, general and administrative expenses	741	724	605
Research and development expenses	176	156	147
Other segment items	(168)	(191)	(108)
Segment income	1,159	1,124	1,024
Restructuring and other costs	(17)	(11)	(68)
Segment assets	1,218	1,150	1,076
Purchases of property, plant and equipment	125	121	112
Depreciation of property, plant and equipment	104	86	75
Operating Segments | Laboratory Products and Biopharma Services
Segment Reporting Information [Line Items]
Consolidated revenues	23,157	23,041	22,511
Cost of revenues	18,074	18,033	17,830
Selling, general and administrative expenses	2,378	2,304	2,347
Research and development expenses	73	68	85
Other segment items	(459)	(722)	(623)
Segment income	3,090	3,358	2,872
Restructuring and other costs	(280)	(295)	(12)
Segment assets	6,145	6,350	6,428
Purchases of property, plant and equipment	971	1,013	1,403
Depreciation of property, plant and equipment	721	669	614
Segment Reconciling Items
Segment Reporting Information [Line Items]
Cost of revenues adjustments	(47)	(95)	(46)
Selling, general and administrative expenses adjustments	8	(59)	(37)
Restructuring and other costs	(379)	(459)	(114)
Amortization of acquisition-related intangible assets	(1,952)	(2,338)	(2,395)
Segment assets	84,031	85,314	83,340
Purchases of property, plant and equipment	85	80	98
Depreciation of property, plant and equipment	0	0	0
Corporate
Segment Reporting Information [Line Items]
Restructuring and other costs	$ (9)	$ (15)	$ (3)

Business Segment and Geograph_5

Business Segment and Geographical Information - Schedule of Revenue by Country Based on Customer Location (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated revenues	$ 42,879	$ 42,857	$ 44,915
Consolidated long-lived assets	10,795	11,004	10,873
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated revenues	21,755	22,013	23,820
Consolidated long-lived assets	6,245	6,352	6,308
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated revenues	21,124	20,844	21,095
Consolidated long-lived assets	$ 4,550	$ 4,652	$ 4,565

Acquisitions - Components of Pu

Acquisitions - Components of Purchase Price and Net Assets Acquired (Details) - USD ($) $ in Millions	Jul. 10, 2024	Aug. 14, 2023	Jan. 03, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill				$ 45,853	$ 44,020	$ 41,196
Olink
Business Acquisition [Line Items]
Cash paid	$ 3,215
Debt settled	28
Cash acquired	(97)
Purchase price	3,146
Goodwill	2,302
Net tangible assets	8
Deferred tax assets (liabilities)	(176)
Net assets acquired	3,146
Olink | Customer relationships
Business Acquisition [Line Items]
Definite-lived intangible assets	708
Olink | Product technology
Business Acquisition [Line Items]
Definite-lived intangible assets	207
Olink | Tradenames
Business Acquisition [Line Items]
Definite-lived intangible assets	$ 97
The Binding Site
Business Acquisition [Line Items]
Cash paid			$ 2,412
Debt settled			307
Cash acquired			(20)
Purchase price			2,699
Goodwill			1,741
Net tangible assets			174
Deferred tax assets (liabilities)			(288)
Net assets acquired			2,699
The Binding Site | Customer relationships
Business Acquisition [Line Items]
Definite-lived intangible assets			868
The Binding Site | Product technology
Business Acquisition [Line Items]
Definite-lived intangible assets			162
The Binding Site | Tradenames
Business Acquisition [Line Items]
Definite-lived intangible assets			42
The Binding Site | Backlog
Business Acquisition [Line Items]
Definite-lived intangible assets			$ 0
CorEvitas
Business Acquisition [Line Items]
Cash paid		$ 730
Debt settled		184
Cash acquired		(4)
Purchase price		910
Goodwill		627
Net tangible assets		(2)
Deferred tax assets (liabilities)		(68)
Net assets acquired		910
CorEvitas | Customer relationships
Business Acquisition [Line Items]
Definite-lived intangible assets		260
CorEvitas | Product technology
Business Acquisition [Line Items]
Definite-lived intangible assets		47
CorEvitas | Tradenames
Business Acquisition [Line Items]
Definite-lived intangible assets		0
CorEvitas | Backlog
Business Acquisition [Line Items]
Definite-lived intangible assets		$ 46

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Weighted-average amortization period		17 years
Customer relationships
Business Acquisition [Line Items]
Weighted-average amortization period	19 years	18 years
Product technology
Business Acquisition [Line Items]
Weighted-average amortization period	15 years	14 years
Tradenames
Business Acquisition [Line Items]
Weighted-average amortization period	15 years	15 years
Backlog
Business Acquisition [Line Items]
Weighted-average amortization period		13 years
Olink
Business Acquisition [Line Items]
Weighted-average amortization period	18 years

Leases- Narrative (Details)

Leases- Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) lease
Lessee, Lease, Description [Line Items]
Leased operating facilities | lease	3
Lease Residual Value Guarantee
Lessee, Lease, Description [Line Items]
Maximum guarantee under lease arrangements | $	$ 147
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 month
Options to extend, renewal term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	30 years
Options to extend, renewal term	10 years
Option to terminate, term	1 year

Leases - Schedule of Operating

Leases - Schedule of Operating Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease costs	$ 353	$ 355	$ 351
Variable lease costs	115	115	109
Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities	327	410	289
Operating lease ROU assets obtained in exchange for new operating lease liabilities	262	234	$ 430
ROU assets - included in other assets	1,489	1,556
Operating lease liabilities - included in other accrued expenses	261	263
Operating lease liabilities - included in other long-term liabilities	$ 1,239	$ 1,244
Remaining operating lease term	8 years 7 months 6 days	9 years 2 months 12 days
Discount rate	4.60%	4%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other accrued expenses	Other accrued expenses
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities	Other accrued expenses

Leases - Schedule of Future Pay

Leases - Schedule of Future Payments of Operating Lease Liabilities (Details) $ in Millions	Dec. 31, 2024 USD ($)
Leases [Abstract]
2025	$ 320
2026	277
2027	235
2028	167
2029	136
2030 and thereafter	723
Total lease payments	1,858
Less: imputed interest	$ 357
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other accrued expenses, Other long-term liabilities
Total operating lease liability	$ 1,501

Pensions and Other Postretireme

Pensions and Other Postretirement Benefit Plans - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan expense	$ 443	$ 468	$ 402
Cash contributions to retirement plans	$ 45	$ 42	$ 41
U.S. equity funds | United States
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	10%
International equity funds | United States
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	10%
Fixed income funds | United States
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	80%
Minimum
Defined Benefit Plan Disclosure [Line Items]
Estimated contributions to plan	$ 40
Minimum | Fixed income funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	30%
Minimum | Equity funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	0%
Minimum | Multi-asset funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	0%
Minimum | Alternative investments | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	0%
Minimum | Real estate funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	0%
Minimum | Derivative funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	0%
Maximum
Defined Benefit Plan Disclosure [Line Items]
Estimated contributions to plan	$ 50
Maximum | Fixed income funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	90%
Maximum | Equity funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	25%
Maximum | Multi-asset funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	40%
Maximum | Alternative investments | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	4%
Maximum | Real estate funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	4%
Maximum | Derivative funds | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Target allocations for investments	45%

Pensions and Other Postretire_2

Pensions and Other Postretirement Benefit Plans - Reconciliation of Benefit Obligations and Plan Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
United States
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 937	$ 1,005
Change in projected benefit obligations
Projected benefit obligation at beginning of year	1,005	995
Acquisitions	0	0
Service costs	0	0	$ 0
Interest costs	46	47	27
Settlements	0	0
Plan participants' contributions	0	0
Actuarial (gains)/losses	(32)	42
Benefits paid	(81)	(79)
Currency translation and other	0	0
Projected benefit obligation at end of year	937	1,005	995
Change in fair value of plan assets
Fair value of plan assets at beginning of year	947	937
Acquisitions	0	0
Actual return on plan assets	22	84
Employer contributions	7	5
Settlements	0	0
Plan participants' contributions	0	0
Benefits paid	(81)	(79)
Currency translation and other	0	0
Fair value of plan assets at end of year	895	947	937
Funded status	(43)	(58)
Amounts recognized in balance sheet
Noncurrent assets	5	0
Current liability	(5)	(6)
Noncurrent liabilities	(42)	(52)
Net amount recognized	(43)	(58)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss/(gain)	218	217
Prior service (credits)/cost	0	0
Net amount recognized	218	217
Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	1,079	1,166
Change in projected benefit obligations
Projected benefit obligation at beginning of year	1,221	1,069
Acquisitions	0	15
Service costs	28	26	34
Interest costs	40	42	20
Settlements	(29)	(37)
Plan participants' contributions	10	9
Actuarial (gains)/losses	(59)	65
Benefits paid	(26)	(25)
Currency translation and other	(49)	57
Projected benefit obligation at end of year	1,135	1,221	1,069
Change in fair value of plan assets
Fair value of plan assets at beginning of year	944	868
Acquisitions	0	15
Actual return on plan assets	(37)	29
Employer contributions	37	36
Settlements	(29)	(37)
Plan participants' contributions	10	9
Benefits paid	(26)	(25)
Currency translation and other	(32)	49
Fair value of plan assets at end of year	867	944	$ 868
Funded status	(268)	(277)
Amounts recognized in balance sheet
Noncurrent assets	57	65
Current liability	(12)	(11)
Noncurrent liabilities	(313)	(331)
Net amount recognized	(268)	(277)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss/(gain)	156	151
Prior service (credits)/cost	(7)	(5)
Net amount recognized	$ 149	$ 146

Pensions and Other Postretire_3

Pensions and Other Postretirement Benefit Plans - Actuarial Assumptions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Components of net benefit cost/(income)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement and Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible List]	Other income/(expense)
United States
Weighted average assumptions used to determine projected benefit obligations
Discount rate for determining benefit obligation	5.48%	4.82%
Interest crediting rate for cash balance plans	5.39%	4.76%
Weighted average assumptions used to determine net benefit cost/(income)
Discount rate - interest cost	4.82%	5.01%	2.70%
Interest crediting rate for cash balance plans	4.76%	4.96%	2.58%
Expected long-term rate of return on assets	6%	6.25%	4.75%
Components of net benefit cost/(income)
Service cost	$ 0	$ 0	$ 0
Interest cost on benefit obligation	46	47	27
Expected return on plan assets	(56)	(59)	(45)
Amortization of actuarial net loss	0	0	4
Amortization of prior service cost/(benefit)	0	0	0
Settlement/curtailment loss/(gain)	0	0	0
Net periodic benefit cost/(income)	$ (10)	$ (12)	$ (14)
Foreign Plan
Weighted average assumptions used to determine projected benefit obligations
Discount rate for determining benefit obligation	3.74%	3.47%
Interest crediting rate for cash balance plans	2.28%	2.06%
Average rate of increase in employee compensation	2.58%	2.64%
Weighted average assumptions used to determine net benefit cost/(income)
Discount rate - service cost	3%	3.62%	1%
Discount rate - interest cost	3.48%	3.95%	1.36%
Interest crediting rate for cash balance plans	2.06%	2.19%	1.25%
Average rate of increase in employee compensation	2.64%	2.77%	2.73%
Expected long-term rate of return on assets	4.28%	4.33%	2.33%
Components of net benefit cost/(income)
Service cost	$ 28	$ 26	$ 34
Interest cost on benefit obligation	40	42	20
Expected return on plan assets	(36)	(37)	(26)
Amortization of actuarial net loss	4	2	7
Amortization of prior service cost/(benefit)	(1)	(1)	(1)
Settlement/curtailment loss/(gain)	2	1	(2)
Net periodic benefit cost/(income)	$ 38	$ 33	$ 32

Pension and Other Postretirem_3

Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation and Fair Value of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Pension plans with projected benefit obligations in excess of plan assets
Projected benefit obligation	$ 727	$ 1,752
Fair value of plan assets	376	1,352
Pension plans with accumulated benefit obligations in excess of plan assets
Accumulated benefit obligation	671	1,695
Fair value of plan assets	$ 376	$ 1,349

Pension and Other Postretirem_4

Pension and Other Postretirement Benefit Plans - Schedule of Estimated Future Benefit Payments (Details) $ in Millions	Dec. 31, 2024 USD ($)
United States
Defined Benefit Plan, Expected Future Benefit Payments [Abstract]
2025	$ 82
2026	81
2027	81
2028	80
2029	79
2030-2034	373
Foreign Plan
Defined Benefit Plan, Expected Future Benefit Payments [Abstract]
2025	54
2026	57
2027	58
2028	62
2029	66
2030-2034	$ 405

Pension and Other Postretirem_5

Pension and Other Postretirement Benefit Plans - Schedule of Fair Value of the Company's Plan Assets (Details) - USD ($) $ in Millions		Dec. 31, 2024	Dec. 31, 2023		Dec. 31, 2022
United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		$ 895	$ 947		$ 937
United States | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		895	947	[1]
United States | U.S. equity funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		91	93
United States | U.S. equity funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | U.S. equity funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | U.S. equity funds | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | U.S. equity funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		91	93	[1]
United States | International equity funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		89	93
United States | International equity funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | International equity funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | International equity funds | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | International equity funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		89	93	[1]
United States | Fixed income funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		692	739
United States | Fixed income funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | Fixed income funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | Fixed income funds | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | Fixed income funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		692	739	[1]
United States | Money market funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		23	22
United States | Money market funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | Money market funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | Money market funds | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
United States | Money market funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		23	22	[1]
Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		867	944		$ 868
Foreign Plan | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		10	13
Foreign Plan | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		325	333
Foreign Plan | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		532	598	[1]
Foreign Plan | Fixed income funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		288	346
Foreign Plan | Fixed income funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		7	9
Foreign Plan | Fixed income funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Fixed income funds | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Fixed income funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		281	337	[1]
Foreign Plan | Equity funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		7	7
Foreign Plan | Equity funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Equity funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Equity funds | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Equity funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		7	7	[1]
Foreign Plan | Multi-asset funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		69	66
Foreign Plan | Multi-asset funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Multi-asset funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Multi-asset funds | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Multi-asset funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		69	66	[1]
Foreign Plan | Derivative funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		169	184
Foreign Plan | Derivative funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Derivative funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Derivative funds | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Derivative funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		169	184	[1]
Foreign Plan | Alternative investments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets			1
Foreign Plan | Alternative investments | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets			0
Foreign Plan | Alternative investments | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets			0
Foreign Plan | Alternative investments | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets			0
Foreign Plan | Alternative investments | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]		1
Foreign Plan | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		325	333
Foreign Plan | Insurance contracts | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Insurance contracts | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		325	333
Foreign Plan | Insurance contracts | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Insurance contracts | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0	[1]
Foreign Plan | Real estate funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets			1
Foreign Plan | Real estate funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets			0
Foreign Plan | Real estate funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	[1]		1
Foreign Plan | Cash / money market funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		9	6
Foreign Plan | Cash / money market funds | Quoted Prices in Active Markets (Level 1)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		4	4
Foreign Plan | Cash / money market funds | Significant Other Observable Inputs (Level 2)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Cash / money market funds | Significant Unobservable Inputs (Level 3)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0	0
Foreign Plan | Cash / money market funds | Fair Value Measured at Net Asset Value Per Share
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		$ 5	$ 2	[1]
[1] Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.

Stock-based Compensation Expe_3

Stock-based Compensation Expense - Schedule of Weighted Average Assumptions used in the Black-Scholes Option Pricing Model (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Expected stock price volatility	25%	25%	26%
Risk free interest rate	4.30%	4.20%	2%
Expected life of options (years)	5 years	4 years 8 months 12 days	4 years 8 months 12 days
Expected annual dividend	0.30%	0.30%	0.20%
Weighted average grant date fair value (in dollars per share)	$ 166.92	$ 159.32	$ 135.07

Stock-based Compensation Expe_4

Stock-based Compensation Expense - Narrative (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value	$ 395	$ 320	$ 336
Granted (in dollars per share)	$ 556.83	$ 545.73	$ 520.83
Fair value of shares vested	$ 165	$ 207	$ 163
Purchase price percentage	95%
Payroll deductions	10%
Shares issued under ESPP (shares)	0.1	0.1	0.2
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 176
Weighted average amortization period	2 years 1 month 6 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 225
Weighted average amortization period	1 year 10 months 24 days

Stock-based Compensation Expe_5

Stock-based Compensation Expense - Schedule of the Company's Option Activity (Details) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Options Outstanding [Roll Forward]
Outstanding, beginning balance (shares) | shares	5
Granted (shares) | shares	1
Exercised (shares) | shares	(1.2)
Canceled/expired (shares) | shares	(0.2)
Outstanding, ending balance (shares) | shares	4.5
Vested and unvested expected to vest (shares) | shares	4.4
Exercisable (shares) | shares	2.6
Weighted average exercise price
Outstanding, beginning of period (in dollars per share) | $ / shares	$ 401.30
Granted (in dollars per share) | $ / shares	554.31
Exercised (in dollars per share) | $ / shares	260.55
Canceled/expired (in dollars per share) | $ / shares	559.45
Outstanding, end of period (in dollars per share) | $ / shares	465.80
Vested and unvested expected to vest (in dollars per share) | $ / shares	462.90
Exercisable (in dollars per share) | $ / shares	$ 403.06
Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	4 years 3 months 18 days
Options vested and expected to vest, weighted average remaining contractual term	4 years 2 months 12 days
Options exercisable, weighted average remaining contractual term	2 years 10 months 24 days
Options outstanding, aggregate intrinsic value | $	$ 358
Options vested and expected to vest, aggregate intrinsic value | $	358
Options exercisable, aggregate intrinsic value | $	$ 350

Stock-based Compensation Expe_6

Stock-based Compensation Expense - Schedule of the Company's Restricted Unit Activity (Details) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unvested Restricted Units [Roll Forward]
Unvested, beginning balance (shares)	0.6
Granted (shares)	0.4
Performance adjustments (shares)	(0.1)
Vested (shares)	(0.3)
Forfeited (shares)	(0.1)
Unvested, ending balance (shares)	0.6	0.6
Restricted Units, Additional Disclosures [Abstract]
Unvested, weighted average grant-date fair value, beginning (in dollars per share)	$ 533.65
Granted (in dollars per share)	556.83	$ 545.73	$ 520.83
Performance adjustments (in dollars per share)	558.66
Vested (in dollars per share)	524.55
Forfeited (in dollars per share)	539.83
Unvested, weighted average grant-date fair value, ending (in dollars per share)	$ 551.81	$ 533.65